Symmetry Surgical (SSRG) 10-K 1 Mar 16 2015 FY Annual report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2016	Feb. 29, 2016	Jul. 04, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Symmetry Surgical Inc.
Entity Central Index Key	1,616,101
Current Fiscal Year End Date	--01-02
Entity Filer Category	Accelerated Filer
Trading Symbol	ssrg
Entity Common Stock, Shares Outstanding		10,731,139
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jan. 2, 2016
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 89.4

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 02, 2016	Jan. 03, 2015
ASSETS:
Cash	$ 8,072	$ 2,994
Accounts receivable, net	10,922	10,070
Inventories	23,076	24,141
Other current assets	1,624	2,417
Total current assets	43,694	39,622
Property and equipment, net	2,258	2,768
Deferred income taxes	24,291	24,411
Goodwill	9,341	7,126
Intangible assets, net of accumulated amortization	73,719	77,903
Other assets	678	219
Total Assets	153,981	152,049
Liabilities:
Accounts payable	6,240	5,283
Accrued wages and benefits	1,785	1,902
Other accrued expenses	1,540	1,417
Contingent purchase liability, current	1,047	0
Accrued income taxes	201	158
Revolving line of credit	0	3,876
Total current liabilities	10,813	12,636
Contingent purchase liability, non-current	1,136	0
Other liabilities	1,019	1,107
Total Liabilities	$ 12,968	$ 13,743
Commitments and contingencies
Stockholders' Equity:
Common Stock, $.0001 par value; 50,000 shares authorized; 10,535 shares issued January 2, 2016; 10,313 shares issued January 3, 2015	$ 1	$ 1
Additional paid-in capital	140,460	138,928
Retained earnings (accumulated deficit)	1,084	(116)
Accumulated other comprehensive loss	(532)	(507)
Total Stockholders' Equity	141,013	138,306
Total Liabilities and Equity	$ 153,981	$ 152,049

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Jan. 02, 2016	Jan. 03, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000	50,000
Common stock, shares issued	10,535	36,795

CONSOLIDATED AND COMBINED STATE

CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Income Statement [Abstract]
Revenue - third parties		$ 84,527	$ 81,104	$ 88,876
Revenue - Symmetry OEM Solutions		0	678	71
Total revenue		84,527	81,782	88,947
Cost of revenue		45,077	46,098	48,394
Gross profit		39,450	35,684	40,553
Sales and marketing expenses		16,920	17,402	18,279
General and administrative expenses		19,546	18,643	20,515
Asset impairment		1,014	55,817	20,105
Operating income (loss)		1,970	(56,178)	(18,346)
Other (income) expense:
Interest expense		222	24	0
Derivatives valuation loss		0	0	242
Other		269	229	38
Income (loss) before income taxes		1,479	(56,431)	(18,626)
Income tax expense (benefit)		279	(20,656)	(6,441)
Net income (loss)		$ 1,200	$ (35,775)	$ (12,185)
Net income (loss) per share:
Basic (in dollars per share)		$ 0.12	$ (3.73)	$ (1.27)
Diluted (in dollars per share)		$ 0.12	$ (3.73)	$ (1.27)
Weighted average common shares and equivalent shares outstanding:
Basic (in shares)	[1]	9,645	9,587	9,587
Diluted (in shares)	[1]	9,688	9,587	9,587
[1]	On December 5, 2014, SMI distributed 9,587 shares of Symmetry Surgical common stock. For periods prior to the separation, the weighted-average basic and diluted shares outstanding were based on the number of shares of Symmetry Surgical common stock outstanding on the distribution date. Refer to Note 19 for information regarding the calculation of basic and diluted net income per share for the year ended January 3, 2015.

CONSOLIDATED AND COMBINED STAT5

CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS (Parenthetical) shares in Thousands	Dec. 05, 2014shares
Income Statement [Abstract]
Common stock, shares outstanding	9,587

CONSOLIDATED AND COMBINED STAT6

CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 1,200	$ (35,775)	$ (12,185)
Other comprehensive income (loss)
Foreign currency translation adjustments	(109)	(305)	33
Pension plan actuarial gain (loss), net of taxes	84	(41)	64
Comprehensive income (loss)	$ 1,175	$ (36,121)	$ (12,088)

CONSOLIDATED AND COMBINED STAT7

CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Net Parent Investment [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, Shares at Dec. 29, 2012		0
Balance at Dec. 29, 2012	$ 200,947	$ 0	$ 0	$ 0	$ 201,205	$ (258)
Comprehensive income:
Net income (loss)	(12,185)				(12,185)
Other comprehensive income (loss)	97					97
Net transfers to Parent	(17,031)				(17,031)
Balance, Shares at Dec. 28, 2013		0
Balance at Dec. 28, 2013	171,828	$ 0	0	0	171,989	(161)
Comprehensive income:
Net transfers from Parent prior to separation	2,599				2,599
Net loss prior to separation	(35,659)				(35,659)
Reclassification of parent company investment in connection with separation			138,929		(138,929)
Issuance of common stock at separation, Shares		9,587
Issuance of common stock at separation		$ 1	(1)
Net loss	(116)			(116)
Net income (loss)	(35,775)
Other comprehensive income (loss)	(346)					(346)
Stock-based compensation		726
Balance, Shares at Jan. 03, 2015		10,313
Balance at Jan. 03, 2015	138,306	$ 1	138,928	(116)	0	(507)
Comprehensive income:
Net income (loss)	1,200			1,200
Other comprehensive income (loss)	(25)					(25)
Stock-based compensation		222
Stock-based compensation	1,532		1,532
Balance, Shares at Jan. 02, 2016		10,535
Balance at Jan. 02, 2016	$ 141,013	$ 1	$ 140,460	$ 1,084	$ 0	$ (532)

CONSOLIDATED AND COMBINED STAT8

CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Operating activities
Net income (loss)	$ 1,200	$ (35,775)	$ (12,185)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	920	956	1,075
Amortization of intangible assets	5,562	5,375	5,027
Amortization of debt issuance costs	100	7	0
Net loss on sale of assets	35	114	423
Asset impairment	1,014	55,817	20,105
Deferred income tax provision	97	(19,822)	(5,187)
Stock-based compensation	1,532	717	625
Derivatives valuation loss	0	0	242
Unrealized foreign currency transaction (gain) loss	(54)	87	117
Change in operating assets and liabilities:
Accounts receivable	(1,187)	3,131	5,952
Due to Symmetry OEM Solutions	0	(1,946)	665
Other assets	701	(333)	(36)
Inventories	2,125	(7,127)	2,321
Current income taxes	57	143	8
Accounts payable	1,066	(1,674)	(316)
Accrued expenses and other	383	(240)	231
Net cash provided by (used in) operating activities	13,551	(570)	19,067
Investing activities
Purchases of property and equipment	(171)	(552)	(1,477)
Proceeds from the sale of property and equipment	4	12	549
Acquisitions	(4,260)	0	0
Net cash used in investing activities	(4,427)	(540)	(928)
Financing activities
Proceeds from Revolving Loan	141	7,559	0
Payments on Revolving Loan	(4,017)	(3,683)	0
Debt issuance costs	0	(441)	0
Net transfers to Symmetry Medical Inc.	0	(142)	(17,656)
Net cash (used in) provided by financing activities	(3,876)	3,293	(17,656)
Effect of exchange rate changes on cash	(170)	163	3
Net increase in cash	5,078	2,346	486
Cash at beginning of period	2,994	648	162
Cash at end of period	8,072	2,994	648
Supplemental disclosures:
Cash paid for interest	119	9	0
Cash paid for income taxes	$ 139	$ 0	$ 0

Description of the Business

Description of the Business	12 Months Ended
	Jan. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of Operations Overview Symmetry Surgical Inc. (the “Company”) is a global marketer and distributor of medical devices with some limited manufacturing focused on the surgery market. The Company offers over 20,000 products and sells primarily to hospitals and surgical centers in the U.S. and countries worldwide. The Company's current product portfolio includes a broad range of reusable stainless steel and titanium, hand-held general and specialty surgical instruments, single use and disposable instruments, electro-surgery instruments, retractor systems, containers and sterilization devices, and ligation clips sold directly to hospitals and other sites of care. These products are typically used in the surgical specialties of neurosurgery, spine, general surgery- open and laparoscopy, microsurgery, OB/Gyn, ophthalmology, otolaryngology / ENT, plastic / reconstructive, peripheral vascular, arthroscopy, orthopedic, pediatrics, cardiovascular, thoracic, and urology in a hospital setting as well as surgery centers and in select physician offices. These products are viewed in two categories by management; Symmetry Surgical Branded Products and Alliance Partners Products. Symmetry Surgical Branded Products include all products sold under brand names managed by the Company whereas Alliance Partners Products are brands the Company distributes for others in defined markets. On August 28, 2015, the Company acquired the assets of Vesocclude Medical, LLC ("Vesocclude Medical" or "Vesocclude") for $4,055 in cash, gross of the Company's 4.8% existing minority interest in Vesocclude, and up to an additional $2,200 in contingent consideration based on the achievement of milestones discussed in Note 4. Vesocclude's portfolio of titanium ligation clips and appliers are used in surgical procedures to close tubal anatomic structures such as blood vessels or ducts. Vesocclude products are primarily sold in the U.S. direct to hospitals but in some territories are sold through stocking distributors and kit packers. Internationally, Vesocclude products are sold through stocking distributors. On December 1, 2015, the Company acquired the patent protected, ultra-low profile, soft-tissue retraction technology and related product portfolio and other assets from privately held Insightra ® Medical for $400 in cash as well as a royalty on future sales with a fair value of $107 as of the date of acquisition. The portfolio, formerly known as ReeTrakt, will be re-launched under the Symmetry Surgical brand as the Symmetry Access™ Low Profile Retractor beginning in the first half of 2016. The Symmetry Access™ Low Profile Retractor is a single-use product with an ultra-low profile that supports minimal/small incision surgical procedures by providing better surgical access and field of view. Symmetry Surgical plans to launch this product through our existing sales channel in the U.S and internationally. Separation from Symmetry Medical Inc. In August 2014, Symmetry Medical Inc. (“SMI”) announced that it had entered into an Agreement and Plan of Merger, dated as of August 4, 2014 (the “Merger Agreement”), by and among SMI, TecoStar Holdings, Inc., Tecomet, Inc., and TecoSym, Inc. (“Merger Sub”), pursuant to which Merger Sub was merged with and into SMI, with SMI continuing as the surviving corporation (the “Merger”). As a result of the Merger, all of the outstanding shares of common stock of Symmetry Surgical Inc. were spun-off to SMI’s stockholders and the holder of each outstanding share of common stock of SMI received one-quarter of a share of common stock of Symmetry Surgical. This is referred to as the “Spin-Off.” In connection with the Spin-Off, SMI entered into a Separation Agreement, dated as of August 4, 2014 (the “Separation Agreement”) with the Company. Pursuant to the Separation Agreement, SMI transferred all of the assets and liabilities of its Symmetry Surgical Business to the Company prior to the consummation of the Merger and the Spin-Off. The Separation Agreement provides for various agreements and arrangements governing the Company's relationship with SMI after the Spin-Off. The Company includes the consolidated operations of Specialty Surgical Instrumentation, Inc. (d/b/a Symmetry Surgical Inc.), Olsen Medical, LLC, Symmetry Surgical Vesocclude, LLC, Symmetry Surgical Netherlands, CV, Symmetry Surgical Netherlands, BV, Symmetry Surgical, GmbH and Symmetry Surgical Switzerland, GmbH.

Basis for Historical Presentati

Basis for Historical Presentation	12 Months Ended
	Jan. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis for Historical Presentation	Basis for Historical Presentation The consolidated and combined financial statements prior to Separation on December 5, 2014 include the allocation of certain assets and liabilities that were historically held at the SMI corporate level but which are specifically identifiable or allocable to Symmetry Surgical. Cash and cash equivalents held by SMI was not allocated to Symmetry Surgical as they were not expected to be transferred to Symmetry Surgical. Long-term debt and short-term borrowings were not allocated to Symmetry Surgical as none of the debt recorded by SMI was directly attributable to or guaranteed by Symmetry Surgical. All historical intracompany transactions and accounts have been eliminated. All historical intercompany transactions between Symmetry Surgical and the OEM Solutions Business have been reflected as related party transactions. All intercompany transactions between Symmetry Surgical and SMI corporate are considered to be effectively settled in the consolidated and combined financial statements of cash flows as financing activity. The historical financial statements of Symmetry Surgical prior to Separation do not necessarily include all of the expenses that would have been incurred had Symmetry Surgical been a separate, stand-alone entity and may not necessarily reflect Symmetry Surgical’s results of operations, financial position and cash flows had Symmetry Surgical been a stand-alone company during the periods presented. These historical financial statements include an allocation of expenses related to certain general and administrative, selling and marketing expenses from SMI to Symmetry Surgical. These expenses have been allocated to Symmetry Surgical first on the basis of direct usage when identifiable, with the remainder allocated on the basis of their respective revenues. Symmetry Surgical considers the expense allocation methodology and results to be reasonable for all pre-separation periods presented. However, the allocation may not be indicative of the actual expenses that would have been incurred had Symmetry Surgical operated as an independent, publicly-traded company for these periods.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jan. 02, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation. The consolidated and combined financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Year End . The Company’s fiscal year is the 52 or 53 week period ending on the Saturday closest to December 31. Fiscal year 2015 was a 52 week year (ending January 2, 2016 ), fiscal year 2014 was a 53 week year (ending January 3, 2015 ), and fiscal year 2013 was a 52 week year (ending December 28, 2013). References in these consolidated and combined financial statements to 2015, 2014 and 2013 refer to these financial periods, respectively. Use of Estimates. Preparation of these consolidated and combined financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates, but management does not believe such differences will materially affect the Company's financial position or results of operations. Business Combinations. The Company records its business combinations under the acquisition method of accounting. Under the acquisition method of accounting, the Company allocates the purchase price of each acquisition to the tangible and identifiable intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition. The fair value of identifiable intangible assets is based upon detailed valuations that use various assumptions made by management. Any excess of the purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Revenue Recognition. The Company recognizes revenue on orders received from its customers when there is persuasive evidence of an arrangement with the customer that is supportive of revenue recognition, the customer has made a fixed commitment to purchase the product for a fixed or determinable price, collection is reasonably assured under the Company’s normal billing and credit terms and ownership and all risks of loss have been transferred to the buyer which is normally upon shipment or delivery to the customer. In certain circumstances, customer terms require receipt of product prior to the transfer of the risk of ownership. In such circumstances, revenue is not recognized upon shipment, but rather upon confirmation of delivery. For product sales to distributors, the Company recognizes revenue upon shipment to the distributor under standard contract terms stating that title to the goods passes to the distributors at point of shipment to the distributor’s location. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product. The Company offers certain customers volume rebates, which are reflected as a reduction in revenue when it is probable the rebate will be earned based on current and forecasted sales and the amount can be estimated. Product returns are estimated based upon historical return rates and are reflected as a reduction of revenue in the same period revenue is recognized. Cash. Cash and cash equivalents include all highly liquid investments with a maturity of three months or less at the time of purchase. Allowance for Doubtful Accounts. The Company performs periodic credit evaluations of customers' financial condition and generally does not require collateral. Receivables are generally due within 30 to 90 days. The Company maintains an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. The Company makes estimates regarding the future ability of its customers to make required payments based on historical credit experience and expected future trends. Provisions to the allowance for doubtful accounts are charged to current selling and marketing expenses. Actual losses are charged against this allowance when incurred. The activity in the allowance for doubtful accounts was as follows: Fiscal Year Ended January 2, 2016 January 3, 2015 December 28, 2013 Balance as of beginning of period $ 306 $ 225 $ 483 Provision (recoveries) 37 481 (69 ) Write-offs (139 ) (400 ) (189 ) Balance as of end of period $ 204 $ 306 $ 225 Concentration of Credit Risk. On an on-going basis, the Company has no financial instruments that represent a concentration of credit risk. Inventories. Inventories are stated at the lower of cost, determined primarily on the first-in, first-out (FIFO) method, or market (net realizable value). Costs include material, labor and overhead costs, as applicable. Inventory balances are reviewed quarterly for excess products or obsolete inventory levels and written down, if necessary, to net realizable value. Property and Equipment. Property and equipment are stated on the basis of cost. Depreciation is calculated on the straight-line method over the estimated useful lives of the respective assets. Accelerated methods are used for income tax purposes. Repair and maintenance costs are charged to expense as incurred. Upon retirement or sale of an asset, its cost and related accumulated depreciation are removed from the consolidated balance sheet and any gain or loss is recorded in operating income or expense. Definite-Lived Long-Lived Assets. The Company assesses the impairment of definite-lived long-lived assets when circumstances indicate the carrying value of an asset may not be recoverable based on the undiscounted future cash flows of an asset. If the carrying amount of the asset is determined not to be recoverable, a write-down to fair value is recorded. Fair values are determined based on quoted market values, undiscounted cash flows, or external appraisals, as applicable. The Company reviews long-lived assets for impairment at the individual asset or the asset group level for which the lowest level of independent cash flows can be identified. Intangible assets subject to amortization consist of trademarks and technology and patents which are amortized using the straight-line method, as well as customer related intangible assets which are amortized on an accelerated method. Straight-line methods are used for income tax purposes. All of the Company’s intangible assets were acquired in connection with its various acquisitions. The Company is required to reassess the expected useful lives of existing definite-lived assets annually. Impairment charges were recorded in fiscal 2015 related to two patents and one trademark of $252 and $762 , respectively. These assets were transitioned from Symmetry Medical during the Spin-Off and are no longer a key focus of the product portfolio given recent acquisitions and other areas of revenue growth. The Company reviewed all other definite-lived long-lived assets and did not record any impairment charges related to the remaining assets for fiscal 2015, 2014 or 2013 . The assessment of the recoverability of long-lived assets reflects management’s assumptions and estimates. Factors that management must estimate when performing impairment tests include sales volume, prices, inflation, discount rates, exchange rates, tax rates and capital spending. Significant management judgment is involved in estimating these factors, and they include inherent uncertainties. Measurement of the recoverability of these assets is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific reporting unit to which the assets are attributed. Changes in these estimates could change the conclusion regarding the impairment of other intangible assets or goodwill (as described below) and potentially result in a non-cash impairment in the future period. During fiscal 2013, all indefinite life intangible assets were evaluated and determined to be definite-lived assets and therefore assigned an appropriate useful life. In connection with the annual impairment test during fiscal 2013, the Company recognized an impairment charge related to certain trademarks and in-process research and development of $1,245 and $610 , respectively. Goodwill. Goodwill recorded by the Company represents the purchase price in excess of the net assets of businesses acquired. Goodwill is not amortized but is tested for impairment annually on the first day of the fourth fiscal quarter and more frequently if circumstances warrant using a two-step process. The first step is a screen for potential impairment, while the second step measures the amount of impairment. Potential impairment is determined by comparing estimated fair value to the net book value of the reporting unit. Fair value is calculated using an income approach based on the present value of estimated future cash flows. The Company completed its impairment test and no impairment of goodwill existed in fiscal 2015. The Company recorded goodwill impairment charges in fiscal 2014 fiscal and 2013 totaling $55,817 and $18,250 , respectively. Income Taxes. Income taxes prior to the Spin-Off are presented on a separate return basis. Prior to the Spin-Off, the Company was included in the consolidated tax return of SMI. The consolidated and combined financial statements of the Company have been prepared using the assets and liability method in accounting for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities. Differences between the anticipated and actual outcomes of these future tax consequences could have a material impact on the consolidated results of operations or financial position of the Company. As a stand-alone entity, the Company files tax returns on its own behalf and its deferred taxes and effective tax rate may differ from those used in the historical periods. The Company did not maintain an income taxes payable to/from account with SMI. With the exception of certain entities outside the U.S. that transferred to the Company at separation, the Company is deemed to settle current tax balances with the SMI tax paying entities in the respective jurisdictions. These settlements are reflected as changes in net parent investment or net transfers to Symmetry Medical Inc. Additionally, tax planning strategies are utilized as part of the global tax compliance program of the Company. Judgments and interpretation of statutes are inherent in this process. The Company provides related reserves, where applicable, in accounting for uncertain tax positions. Interest and penalties associated with reserves for uncertain tax positions are classified in income tax expense in the statements of operations. During fiscal 2015, the Company identified an immaterial error in which deferred tax assets and additional paid-in capital were understated by $352 at the separation date from SMI in December 2014. The Company corrected the error in the accompanying January 3, 2015 consolidated balance sheet and consolidated and combined statements of equity. Pensions. The Company engages outside actuaries to assist in the determination of the obligation and cost under the plan which are direct obligations of the Company. The valuation of the funded status and the net period benefit cost for this plan is calculated using actuarial assumptions. The significant assumptions, which are reviewed annually, include the discount rate, compensation increases, turnover rates and health care cost trend rates. The significant assumptions used in determining these calculations are disclosed in Note 8 to the consolidated and combined financial statements. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method, in accordance with the rules for accounting for post-employment benefits. Foreign Currency Translation. The financial statements of the Company's foreign subsidiaries are accounted for in local currency and have been translated into U.S. dollars in accordance with accounting guidance on foreign currency translation. Assets and liabilities have been translated using the exchange rate in effect at the balance sheet date. Revenues and expenses have been translated using a weighted-average exchange rate for the period. Currency translation adjustments have been recorded as a separate component of equity. Foreign currency transaction gains and losses resulting from a subsidiary's foreign currency denominated assets and liabilities included in other income were losses of $309 , $195 and $49 in fiscal 2015, 2014 and 2013 , respectively. Shipping and Handling Costs. The Company reflects freight costs associated with shipping its products to customers as a component of cost of revenue. Advertising Costs. Advertising costs are expensed as incurred and were $552 , $444 and $728 in fiscal 2015, 2014 and 2013 , respectively. Research and Development Costs. The Company recognizes costs associated with research and development (R&D) within general and administrative expenses in the consolidated and combined statements of operations. R&D costs were $1,174 , $721 and $864 in fiscal 2015, 2014 and 2013, respectively. Derivative Financial Instruments. The Company recognizes all derivative instruments in its consolidated and combined financial statements at fair value. Changes in the fair value of derivatives are recorded each period in the derivative valuation loss line item of the consolidated and combined statements of operations unless the derivative qualifies for hedge accounting in which case the realized changes in fair value are reflected in the same financial statement line item of the item being hedged or the effective portion of changes in fair value of hedges is recorded each period in accumulated other comprehensive income (loss), net of tax, until the related hedge transaction occurs. Any ineffective portion of changes in fair value of the hedges is recorded in the derivative valuation loss line item of the statement of operations. Stock-based compensation. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. Compensation cost for service-based awards is recognized ratably over the applicable service period. Compensation cost for performance-based awards is reassessed each period and recognized based upon the probability that the performance targets will be achieved. For restricted stock subject to service conditions or with performance targets, the fair market value of the award is determined based upon the closing value of the Company’s stock price on the grant date and the amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. For restricted stock with service conditions or with performance targets, the total expense recognized for each grant is only for those awards that ultimately vest. Product Warranty. The Company offers a limited warranty for its products with a coverage period that ranges between 1 year to lifetime for materials and workmanship. Warranty coverage varies depending on the product family. The Company’s policy is to accrue the estimated cost of warranty coverage at the time of the sale. The following table presents the change in the product warranty accrual included in other accrued expenses. Fiscal Year Ended January 2, 2016 January 3, 2015 December 28, 2013 Balance as of beginning of period $ 321 $ 555 $ 235 Provision for warranties issued in current year 157 201 105 Provision for (recover of) pre-existing warranty, net — (157 ) 325 Payments (129 ) (278 ) (110 ) Balance as of end of period $ 349 $ 321 $ 555 Recently Issued and Adopted Accounting Pronouncements On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies and the Company has chosen to take advantage of this extended transition period. Revenue from Contracts with Customers: In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 was originally effective for fiscal periods (including interim periods) beginning after December 15, 2016. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date by one year, with early adoption permitted as of the original effective date. ASU 2014-09 allows for either a full retrospective or a modified retrospective transition method. The Company is currently assessing the potential impact of the adoption of ASU 2014-09 on its financial statements and related disclosures. Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity : In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360), Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This update modifies the requirements for reporting discontinued operations. Under the amendments in ASU 2014-08, the definition of discontinued operation has been modified to only include those disposals of an entity that represent a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. This update also expands the disclosure requirements for disposals that meet the definition of a discontinued operation and requires entities to disclose information about disposals of individually significant components that do not meet the definition of discontinued operations. This update is effective for annual and interim periods beginning after December 15, 2014. The adoption of this ASU in fiscal 2015 by the Company did not have an impact on its financial position, results of operations or cash flows. Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. In June, 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This new guidance states that a performance target that affects vesting of a share-based payment and that could be achieved after the requisite service period is a performance condition under ASC 718. This update is effective for annual and interim periods beginning after December 15, 2015. The Company does not believe this ASU will have an impact on the Company's financial statements. Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In August, 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. This new guidance requires management to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The standard is effective for annual periods ending after December 15, 2016 with early adoption permitted. The Company does not believe this ASU will have an impact on the Company’s financial statements. Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This new guidance requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments of this standard are effective prospectively for the fiscal years, including interim periods, beginning after December 15, 2015, and early adoption is permitted. The Company adopted this ASU on January 3, 2016. Income Taxes (Topic 740) Related to the Balance Sheet Classification of Deferred Taxes. In November 2014 the FASB issued ASU 2015-17, Income Taxes (Topic 740) Related to the Balance Sheet Classification of Deferred Taxes which will require entities to present deferred tax assets (DTAs) and deferred tax liabilities (DTLs) as noncurrent in a classified balance sheet. The ASU simplifies the current guidance (ASC 740-10-45-4), which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet. The ASU is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods. The Board decided to allow all entities to early adopt the ASU for financial statements that had not been issued. Therefore, the Company adopted this ASU at January 2, 2016, and has reclassified all prior periods to be consistent with the requirements outlined in the ASU. The impact of the prior period reclassification was a $2,816 reduction of current assets, a $15 reduction of current liabilities and a net working capital decrease of $2,801 at January 3, 2015. Technical Corrections and Improvements . In June 2015, the FASB issued ASU No. 2015-10, Technical Corrections and Improvements to clarify that, for nonrecurring measurements estimated at a date during the reporting period other than the end of the reporting period, an entity should clearly indicate that the fair value information presented is not as of the period's end as well as the date or period that the measurement was taken. The Company adopted ASU 2015-10, effective June 12, 2015, as the change was effective upon issuance. The adoption did not have an impact on the Company's consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 02, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions On August 28, 2015, the Company acquired the assets of Vesocclude for $4,055 in cash and up to an additional $2,200 in contingent consideration; each of which are gross of the Company's 4.8% existing minority interest in Vesocclude. The contingent consideration involves two contingent purchase payments. Contingent purchase liability No. 1 is based on achieving certain milestones related to new product introduction. Contingent purchase liability No. 2 is based on reaching specified new product commercial sales levels. The settlement of these contingent purchase liabilities can be made in cash or the Company's common stock or any combination thereof at the Company's option. Vesocclude's portfolio of titanium ligation clips and appliers are used in surgical procedures to close tubal anatomic structures such as blood vessels or ducts. Vesocclude products are primarily sold in the U.S. direct to hospitals but in some territories are sold through stocking distributors and kit packers. Internationally, Vesocclude products are sold through stocking distributors. The Company believes the Vesocclude acquisition further expands its Symmetry Surgical branded product offerings and augments the geographic coverage of its sales force as well as allows Symmetry Surgical to extend its brand through the legacy Vesocclude sales channels both in the US and internationally. Prior to the acquisition date, the Company accounted for its 4.8% minority interest as an equity-method investment. Pursuant to current accounting standards, the Company recorded 100% of the assets and liabilities acquired at their fair values, and recognized a $67 non-cash gain representing the difference between the fair value (based on the purchase price less a control premium) and the equity method carrying value of the investment at the acquisition date. The gain is included in the line item "Other income" in the consolidated statements of operations. The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets acquired and liabilities assumed based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Net cash consideration $ 3,860 Contingent purchase liability No. 1, current 1,034 Contingent purchase liability No. 2, non-current 1,013 Pre-existing ownership interest 186 Gain on pre-existing ownership interest 67 Fair value of total consideration $ 6,160 Inventory $ 962 Property and equipment 252 Acquired customers 1,010 Trademarks 280 Acquired technology and patents 800 Other assets, non-current 637 Non-compete 25 Net identifiable assets acquired $ 3,966 Goodwill $ 2,194 Cash paid for acquisition $ 4,055 Cash received from seller related to previous ownership interest 195 Net cash transferred to seller upon closing $ 3,860 In accordance with accounting guidance, the Company estimated the fair value of the contingent consideration as of the acquisition date and included such contingent purchase liabilities as a component of total purchase price as noted above. The potential undiscounted amount of each future payment that the Company could be required to make under the agreement is between $0 and $2,200 in the aggregate. The fair value of the contingent consideration arrangement of $2,047 was estimated by applying a market approach. That measure is based on significant inputs that are not observable in the market, also referred to as Level 3 inputs. Key assumptions include a discount rate of 18.61% and an estimated level of probability. Changes to the fair value of the contingent consideration, subsequent to the initial purchase date, have been reflected in the statement of operations, which totaled $26 in fiscal 2015. The purchase price of Vesocclude exceeded the fair value of net identifiable tangible and intangible assets. Goodwill recorded is deductible for U.S. Federal income taxes. The purchase was accounted for as a business combination and the results of Vesocclude have been included in the Company's consolidated statements of operations since the date of acquisition. The pro forma impact of the acquisition on the Company's prior period consolidated statements of operations was not material. The acquisition includes a 20% minority interest in a medical device company and an option to purchase the remaining ownership interest. The Company has accounted for its 20% ownership interest as an equity method investment. On December 1, 2015, the Company acquired the patent protected, ultra-low profile, soft-tissue retraction technology and related product portfolio and other assets from privately held Insightra ® Medical for $400 in cash as well as a royalty on future sales. This royalty has been deemed a contingent purchase liability with a fair value of $107 as of the date of acquisition. The portfolio, formerly known as ReeTrakt, will be re-launched under the Symmetry Surgical brand as the Symmetry Access™ Low Profile Retractor beginning in the first half of 2016. The Symmetry Access™ Low Profile Retractor is a single-use product with an ultra-low profile that supports minimal/small incision surgical procedures by providing better surgical access and field of view. The product is designed to minimize tissue damage by providing gentle and adjustable tissue retraction without a bridge, arms or handles that reduce access to the surgical site. The portfolio offers a variety of tissue retraction tips and adheres securely to the surgical drape or skin, eliminating the need for hand-held retraction during a case. The Company believes this acquisition further expands its Symmetry Surgical branded product offerings. The Company plans to launch this product as a Symmetry Surgical branded product offering through its existing sales channel in the U.S and internationally. The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets acquired and liabilities assumed based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Cash consideration $ 400 Contingent purchase liability No. 3, non-current 107 Fair value of total consideration $ 507 Inventory $ 102 Property and equipment 30 Acquired technology and patents 341 Non-compete 5 Net identifiable assets acquired $ 478 Goodwill $ 29 The purchase price of Insightra Medical exceeded the fair value of net identifiable tangible and intangible assets. Goodwill recorded is deductible for U.S. Federal income taxes. The purchase was accounted for as a business combination and the results of this acquisition did not have any significant impact to the 2015 consolidated statements of operations since its date of acquisition. The pro forma impact of the acquisition on the Company's prior period consolidated statements of operations was not material.

Inventories

Inventories	12 Months Ended
	Jan. 02, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: January 2, January 3, Raw materials $ 1,032 $ 880 Work-in-process 141 530 Finished goods 21,903 22,731 $ 23,076 $ 24,141

Property and Equipment

Property and Equipment	12 Months Ended
	Jan. 02, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment, including depreciable lives, consists of the following: January 2, January 3, Buildings and improvements (20 to 40 years) $ 560 $ 575 Machinery and equipment (5 to 15 years) 1,816 1,499 Office equipment (3 to 5 years) 3,686 4,039 Construction-in-progress 10 43 6,072 6,156 Less accumulated depreciation (3,814 ) (3,388 ) $ 2,258 $ 2,768

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Jan. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The Company has one operating segment that represents the lowest level for which discrete financial information is available and the operating results are regularly reviewed by management. Prior to performing the annual goodwill impairment test step 1 analysis, the Company tested long-lived assets to be held and used for impairment on an undiscounted cash flow basis using a risk-adjusted discount rate. See Note 3 for the results of this testing. To derive the fair value of the reporting unit, as required in step one of the goodwill impairment test, the Company uses the income approach, specifically the discounted cash flow method, to determine the fair value of the reporting unit. This approach calculates fair value by estimating the after-tax cash flows attributable to the reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. Inputs used to fair value the Company's reporting unit are considered Level 3 inputs of the fair value hierarchy and include the following: • The Company's financial projections for its reporting unit are based on management's assessment of macroeconomic variables, industry trends and market opportunities, as well as the Company's strategic objectives and future growth plans. Revenue growth rates assumed in fiscal 2015 for the Company's reporting unit were approximately 0.0% - 5.7% for fiscal 2016 and beyond. Revenue growth rates assumed in fiscal 2014 and fiscal 2013 for the Company's reporting unit were approximately 3- 5% and 3- 6% , respectively, for fiscal 2015 and beyond. • The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data, as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise. The discount rate used was approximately 12.0% in fiscal 2015, 15.0% in fiscal 2014 and 12.5% in fiscal 2013. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. In the second step, the Company assigned the reporting unit's fair value to all of its assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the reporting unit were being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment charge. This allocation process was performed only for the purposes of measuring the goodwill impairment and not to adjust the carrying values of the recognized assets and liabilities. During fiscal 2015, we determined that no impairment of goodwill existed. During fiscal 2015, we did impair certain definite-lived intangible assets aggregating $1,014 transitioned from Symmetry Medical during the Spin-Off that are no longer a key focus of the product portfolio given recent acquisitions and other areas of revenue growth. Accordingly, the fair value of these assets was determined to be negligible and was written off in full. During fiscal 2013, we impaired certain definite-lived intangible assets totaling $1,855 . There were no definite-lived intangible impairments in fiscal 2014. During fiscal 2014 and fiscal 2013, the Company determined that the expected operating results for the Symmetry Surgical reporting unit were projected to be substantially lower than previous forecasts. Given this information, the Company conducted its interim and annual impairment tests, as applicable, and determined that impairment existed. The Company recorded pre-tax non-cash charges of $55,817 in fiscal 2014 for goodwill and $20,105 in total for fiscal 2013, $18,250 for goodwill and $1,855 of other assets (as described above) and these charges have been recorded in the Company's consolidated and combined statements of operations within the asset impairment line item. The fiscal 2014 impairment was primarily driven by the market valuation of the Company combined with lower revenue due to a sluggish hospital spending environment in the U.S. and previously disclosed integration challenges related to the 2011 acquisition of the surgical instruments portfolio of Codman and Shurtleff, Inc., from which the Company has not recovered as quickly as previously expected and reduced cost savings estimates for the post Spin-off operations of the Company which have also been previously disclosed. As of January 2, 2016 , the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets Acquired customers 19 years $ 92,355 $ (22,961 ) $ 69,394 Trademarks 13 years 4,014 (866 ) 3,148 Acquired technology, patents and other 13 years 1,521 (344 ) 1,177 Intangible assets subject to amortization 19 years $ 97,890 $ (24,171 ) $ 73,719 As of January 3, 2015 , the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets Acquired customers 19 years $ 91,438 $ (17,986 ) $ 73,452 Trademarks 10 years 4,815 (730 ) 4,085 Acquired technology and patents 13 years 1,220 (854 ) 366 Intangible assets subject to amortization 19 years $ 97,473 $ (19,570 ) $ 77,903 Intangible asset amortization expense for fiscal 2015, 2014 and 2013 was $5,562 , $5,375 and $5,027 , respectively, and is included in general and administrative expenses in the consolidated and combined statements of operations. At January 2, 2016, the annual amortization expense for intangible assets recorded as of January 2, 2016 is anticipated to be as follows for each of the next 5 fiscal years: 2016 $ 5,400 2017 5,427 2018 5,378 2019 5,321 2020 5,262 The reconciliation of the beginning and ending carrying amounts of goodwill are as follows: Balance as of December 28, 2013 $ 62,995 Impairment of goodwill (55,817 ) Effects of foreign currency (52 ) Balance as of January 3, 2015 $ 7,126 Acquisitions 2,223 Effects of foreign currency (8 ) Balance as of January 2, 2016 $ 9,341 Accumulated goodwill impairment losses as of January 2, 2016 and January 3, 2015 were $74,067 .

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jan. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company sponsors one defined benefit pension plan for the benefit of its employees at its German subsidiary, which is a legacy plan of the Codman surgical instruments business acquired during the year ended December 31, 2011. The plan is unfunded and provides defined benefits based on the final average salary of the employees as defined in the plan. The components of net periodic pension cost for fiscal 2015 are as follows: Fiscal Year Ended 2015 2014 2013 Components of Net Periodic Pension Cost: Service cost $ 40 $ 46 $ 50 Interest cost 20 26 22 Amortization of net actuarial loss 19 9 16 Net periodic pension cost $ 79 $ 81 $ 88 Weighted average assumptions used to determine net periodic pension cost: Discount rate 2.40 % 3.60 % 3.00 % Salary increases 2.50 % 2.50 % 2.50 % The change in the projected benefit obligation and the funded status of the plan and a reconciliation of such funded status to the amounts reported in the consolidated balance sheets as of January 2, 2016 and January 3, 2015 is as follows: Fiscal Year Ended 2015 2014 2013 Change in projected benefit obligation Benefit obligation, beginning of year $ 900 $ 813 $ 793 Service cost 40 46 50 Interest cost 20 26 22 Actuarial (gain) loss (85 ) 106 (117 ) Foreign currency exchange rate changes (71 ) (91 ) 65 Benefit obligation, end of year $ 804 $ 900 $ 813 Change in fair value of assets: Fair value of plan assets, beginning of year $ — $ — $ — Fair value of plan assets, end of year — — — Funded status at end of year - under funded $ (804 ) $ (900 ) $ (813 ) The following summarizes the Company's balance sheet related pension and other benefit plan accounts at January 2, 2016 as compared to accounts at January 3, 2015 : Fiscal Year Ended 2015 2014 Non-current benefit liability $ 804 $ 900 Accumulated other comprehensive loss, net of tax $ 154 $ 238 No contributions were made during fiscal 2015 to the plan, nor are any contributions expected to be made to the plan in fiscal 2016 , since the plan is unfunded. The accumulated benefit obligation for the plan was $660 and $732 at January 2, 2016 and January 3, 2015 , respectively. The amounts recognized in accumulated other comprehensive income as of January 2, 2016 and January 3, 2015 was as follows: Fiscal Year Ended 2015 2014 2013 Net actuarial (gain) loss $ (85 ) $ 106 $ (117 ) Less: Tax expense (benefit) 1 (65 ) 53 Accumulated other comprehensive (income) loss impact $ (84 ) $ 41 $ (64 ) Weighted average assumptions used to determine benefit obligation: Discount rate 2.49 % 2.40 % 3.60 % Salary increases 2.80 % 2.50 % 2.50 % The net actuarial loss for the pension plan required to be amortized from accumulated other comprehensive income into net periodic pension cost in fiscal 2015 is expected to be $13 . There are no significant benefits under the plan which are expected to be paid from fiscal 2016 through fiscal 2020.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jan. 02, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. As of January 2, 2016, the Company held contingent purchase liabilities required to be measured at fair value on a recurring basis. The Company's contingent purchase liabilities associated with the acquisitions of Vesocclude Medical and Insightra Medical are not observable. The fair value of these liabilities have unobservable inputs in which little or no market data exists, therefore requiring the Company to categorize these liabilities as Level 3 and to re-measure the liabilities using its own assumptions in accordance with ASC 820. The contingent liabilities will continue to be accounted for and measured at fair value until the contingencies are settled or expire. The fair value and carrying value of the Company's liabilities measured at fair value on a recurring basis is as follows (None at January 3, 2015): January 2, 2016 Fair Value Measurements Level 1 Level 2 Level 3 Total Liabilities Contingent purchase liability No. 1 $ — $ — $ 1,047 $ 1,047 Contingent purchase liability No. 2 1,029 1,029 Contingent purchase liability No. 3 — — 107 107 Total liabilities $ — $ — $ 2,183 $ 2,183 Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis and are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment. Assets and liabilities acquired in business combinations (see Note 4) are recorded at their fair value as of the date of acquisition. The Company has performed annual and interim impairment tests for goodwill. The fair value of the reporting unit is determined using the income approach. The income approach focuses on the income-producing capability of an asset, measuring the current value of the asset by calculating the present value of its future economic benefits such as cash earnings, cost savings, tax structure and product offerings. Value indications are developed by discounting expected cash flows to their present value at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation and risks associated with the reporting unit. These assets are classified within Level 3, in the event that the Company was required to measure and record such assets at fair value within its consolidated and combined financial statements, as discussed in Note 7, Goodwill and Other Intangible Assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used, including definite-lived intangible assets and property and equipment, when events or circumstances warrant such a review. Fair value is determined primarily using anticipated cash flows assumed by a market participant, discounted at a rate commensurate with the risk involved and these assets would generally be classified within Level 3, in the event that the Company were required to measure and record such assets at fair value within its consolidated and combined financial statements. The interest rates on the Company's borrowings under the revolving credit facility are adjusted regularly to reflect current market rates and thus carrying value approximates fair value for these borrowings as there is no active market for our Revolving Loan which is classified as Level 3.

Derivatives

Derivatives	12 Months Ended
	Jan. 02, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The Company utilizes derivative instruments to minimize the volatility of cash flows and statement of operations impacts associated with the impact of fluctuations in foreign currency. The Company recognizes all derivative instruments as either assets or liabilities at fair value on the consolidated balance sheets. Derivative asset and liability amounts with the same counterparty are netted against each other for financial reporting purposes. The Company utilizes third party valuations to assist in the determination of the fair value of these derivatives. The Company considered its derivative instrument valuations to be Level 2 fair value measurements. In June and July 2012, the Company entered into forward swap contracts to mitigate the impact of fluctuations in foreign currency on the statement of operations. As of January 2, 2016 and January 3, 2015 , the Company had settled all of its outstanding forward swap contracts. These swap contracts were not designated as cash flow hedges and therefore the change in the fair value was immediately recorded in derivatives valuation (gain) loss in the consolidated and combined statements of operations for the period ended December 28, 2013.

Debt Arrangements

Debt Arrangements	12 Months Ended
	Jan. 02, 2016
Debt Disclosure [Abstract]
Debt Arrangements	Debt Arrangements On December 5, 2014, the Company, Specialty Surgical Instrumentation, Inc. and Olsen Medical, LLC (collectively, the “Borrowers”) entered into a Credit Agreement (the “Credit Agreement”) with Capital One (formerly known as General Electric Capital Corporation "GECC"), which provides for a revolving loan of up to $20,000 , subject to a borrowing base limitation (the "Revolving Loan"). The Credit Agreement, which is senior and secured, had $0 outstanding as of January 2, 2016 and an aggregate of $3,876 outstanding as of January 3, 2015. Any amounts outstanding under the Revolving Loan are due and payable on December 5, 2019. Amounts outstanding under the Credit Agreement bear interest at LIBOR plus 3.25% , or the Base Rate (which will generally be based on the prime rate as published by the Wall Street Journal from time to time) plus 2.25% . Borrowings under the Revolving Loan are classified as current as of January 3, 2015 due to the existence of cash dominion by Capital One. In February 2015, the Company amended the Credit Agreement to allow for a collateral cash account which is excluded from the cash dominion. This collateral cash account is included in current other assets in the consolidated balance sheets. In August 2015, the Company amended the Credit Agreement to allow for the acquisition of Vesocclude Medical. The Company has deferred debt issuance costs related to the Revolving Loan of $346 and $434 as of January 2, 2016 and January 3, 2015, respectively, reflected in current other assets in the consolidated balance sheets. The Credit Agreement is guaranteed by Symmetry Surgical International, Inc., Symmetry Surgical Vesocclude LLC, S.S.I.I. LP, LLC and Symmetry Medical SSI Real Estate LLC (collectively the “Guarantors”). The Revolving Loan is secured by a first-priority perfected security interest in substantially all of the tangible and intangible assets of the Borrowers and the Guarantors, including a pledge of 100% of the equity interests of each domestic subsidiary. The Credit Agreement includes customary covenants for facilities of this type, including limitations on indebtedness, liens, investments and acquisitions, loans and advances, mergers and consolidations, sales of assets, and dividends, stock repurchases and other restricted payments. In addition, the Credit Agreement requires that Borrowers maintain a minimum fixed charge coverage ratio of 1.25 to 1.00 tested at the close of each fiscal quarter beginning March 31, 2015, based on the preceding four fiscal quarters, and maintain at all times minimum liquidity (the sum of cash, cash equivalent and available borrowing capacity under the borrowing base) of $1,500 , tested monthly. As of January 2, 2016, the borrowing base limitation was $13,735 and fully available. The Company was in compliance with all covenants as of January 2, 2016 . See Note 4 for contingent purchase liabilities related to the Vesocclude and Insightra acquisitions.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Jan. 02, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income Accumulated other comprehensive income is comprised of gains (losses) resulting from currency translations of foreign entities and pension plan actuarial gains and losses, net of tax. Other comprehensive income consists of the following: Foreign Currency Translation Pension Plan Actuarial Loss, net of tax Other Comprehensive Income (loss) Balance at December 28, 2013 $ 36 $ (197 ) $ (161 ) Other comprehensive income (loss) (305 ) (41 ) (346 ) Balance at January 3, 2015 (269 ) (238 ) (507 ) Other comprehensive income (loss) (109 ) 84 (25 ) Balance at January 2, 2016 $ (378 ) $ (154 ) $ (532 )

Net Transfers to Symmetry Medic

Net Transfers to Symmetry Medical Inc.	12 Months Ended
	Jan. 02, 2016
Former Parent Company Investment [Abstract]
Net Transfers to Symmetry Medical Inc.	Net Transfers to Symmetry Medical Inc. Net transfers to Symmetry Medical Inc. in the consolidated and combined statements of cash flow represent changes in amounts owed to or due from SMI. Prior to the Spin-Off, these were presented within net parent investment on the combined balance sheet and represented SMI's initial investment in the Company, subsequent allocations of expenses, and advances and receipts of cash resulting from the operations of the U.S. business with SMI. The balance reflected the U.S. based Company’s participation in SMI’s U.S. centralized cash management program under which all of the U.S. Company’s cash receipts were remitted to SMI and all cash disbursements were funded by SMI. Other transactions that affected net parent investment included general and administrative expenses incurred by SMI and allocated to the Company. Subsequent to the Spin-Off, the Company no longer participates in cash management and funding arrangements with SMI.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jan. 02, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party transactions of the Company include the purchase and sale of surgical instruments and cases between SMI's OEM Solutions Business and the Company, centralized cash and debt management in the U.S. and the allocation of certain general and administrative, selling and marketing and research and development expenses from SMI to the Company, prior to separation. Sales of surgical instruments and cases from the Company to SMI's OEM Solutions business were recorded at intercompany transfer prices and totaled $678 and $71 in fiscal 2014 and 2013, respectively. Purchases of surgical instruments and cases from SMI's OEM Solutions business by the Company were recorded at intercompany transfer prices and totaled $6,714 and $5,381 in fiscal 2014 and 2013, respectively. The U.S. based portion of the Company participated in SMI's U.S. centralized cash management program under which all of the U.S. Company’s cash receipts were remitted to SMI and all cash disbursements were funded by SMI. The cash receipts were not kept at specific accounts and instead commingled with cash from other SMI entities. As cash was disbursed and received by SMI prior to separation, it has been accounted for through net parent investment. During fiscal 2014 and 2013, SMI provided various general and administrative and selling and marketing services to the Company including legal assistance, marketing services, human resources, financial reporting and analysis, information technology and insurance management, as well as research and development services. It was SMI's policy to charge these expenses first on the basis of direct usage when identifiable, with the remainder allocated among SMI’s subsidiaries on the basis of their respective revenue. These allocations totaled $5,996 and $6,832 for fiscal 2014 and 2013, respectively. These charges may not be indicative of the actual expense that would have been incurred had the Company operated as an independent, publicly-traded company for the periods presented.

Income Taxes

Income Taxes	12 Months Ended
	Jan. 02, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income before income taxes consisted of: Fiscal Year Ended 2015 2014 2013 Domestic $ 795 $ (57,545 ) $ (19,016 ) Foreign 684 1,114 390 $ 1,479 $ (56,431 ) $ (18,626 ) Significant components of the Company’s net deferred tax assets are as follows: January 2, 2016 January 3, 2015 Deferred tax asset Compensation $ 708 $ 162 Inventory 2,320 2,317 Loss carryforwards 3,555 2,555 Intangibles 17,442 19,139 Other 514 624 Total deferred tax asset 24,539 24,797 Deferred tax liability Property and equipment (254 ) (401 ) Total deferred tax liabilities (254 ) (401 ) Deferred tax assets, net $ 24,285 $ 24,396 Significant components of the income tax provision are as follows: Fiscal Year 2015 2014 2013 Current: Federal $ — $ — $ (1,435 ) State 31 40 159 Foreign 176 148 50 207 188 (1,226 ) Deferred 72 (20,844 ) (5,215 ) $ 279 $ (20,656 ) $ (6,441 ) The provision for income taxes differs from that computed at the federal statutory rate of 34% in 2015 and 35% in 2014 and 2013 as follows: Fiscal Year 2015 2014 2013 Tax at Federal statutory rate $ 503 $ (19,747 ) $ (6,519 ) State income taxes 81 (1,618 ) (552 ) Change in state deferred tax rate (231 ) — — Foreign income taxes (95 ) (250 ) 103 Goodwill impairment — 871 310 Other 21 88 217 $ 279 $ (20,656 ) $ (6,441 ) At January 2, 2016 , the Company had a Federal net operating loss carryforward of approximately $8,432 and various multistate income tax net operating loss carryforwards of approximately $18,160 which have been recorded as a deferred tax asset of approximately $3,555 . The net operating loss carryforwards begin to expire in 2032. No provision has been made for United States federal and state or foreign taxes that may result from future remittances of undistributed earnings of foreign subsidiaries because it is expected that such earnings will be reinvested in these foreign operations indefinitely. At January 2, 2016, we had an aggregate of $1,702 of unremitted earnings of foreign subsidiaries that have been or are intended to be permanently reinvested for continued use in foreign operations. As of January 2, 2016, the Company is subject to unexpired statutes of limitations for U.S. federal income taxes for the years 2012-2014. The Company is also subject to unexpired statutes of limitations for various states, most significantly Tennessee, generally for the years 2012-2014. The Company assesses, on a quarterly basis, the realizability of its deferred tax assets by evaluating all available evidence, both positive and negative, including: (1) the cumulative results of operations in recent years, (2) the nature of recent losses, (3) estimates of future taxable income and (4) the length of operating loss carryforward periods. After considering both the positive and negative evidence management determined that it was more-likely-than-not that it would realize the value of its deferred tax assets. As a result, the Company did not record a valuation allowance against its net deferred tax assets as of January 2, 2016. Realization of the deferred tax asset is dependent upon the Company achieving approximately $63,000 of income before income taxes prior to expiration.

Profit Sharing Plan

Profit Sharing Plan	12 Months Ended
	Jan. 02, 2016
Profit Sharing Plan [Abstract]
Profit Sharing Plan	Profit Sharing Plan During fiscal 2015, the Company maintained a profit sharing plan, which qualifies for favorable tax treatment under Section 401(k) of the Internal Revenue Code. During fiscal 2014 and 2013, SMI maintained a profit sharing plan, which qualified for favorable tax treatment under Section 401(k) of the Internal Revenue Code. Contributions by both the Company and SMI were based upon both discretionary and matching nondiscretionary amounts. The matching amounts represent a 50% match of employees’ contributions, up to a maximum of $4 per participant per year. Expense recorded by the Company for the plans was $222 , $260 and $265 for 2015, 2014 and 2013 , respectively.

Stock-Based Compensation Plans

Stock-Based Compensation Plans	12 Months Ended
	Jan. 02, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Plans	Stock-Based Compensation Plans The Equity Incentive Plan. The Equity Incentive Plan ("the Plan") is designed to enable us to attract, retain and motivate our directors, officers, employees and others who perform services for the Company and its subsidiaries, and to further align their interests with those of the Company’s stockholders, by providing for or increasing their ownership interests in our Company. The Plan provides for the issuance of stock options, stock appreciation rights (“SARs”), restricted stock, deferred stock, dividend equivalents, other stock-based awards and performance awards. Performance awards are based on the achievement of one or more business or personal criteria or goals, as determined by the compensation committee and approved by the Board of Directors (and independent directors for awards made to executive officers and the Board of Directors). An aggregate of 1,250 shares of common stock are now reserved for issuance under the Plan, subject to certain adjustment reflecting changes in the Company's capitalization. The Company provides newly issued shares to satisfy stock option exercises and issuance of SARs, restricted stock, deferred stock, dividend equivalents, other stock-based awards and performance awards. Restricted stock is a grant of shares of common stock that may not be sold or disposed of, and that may be forfeited in the event of certain terminations of employment, prior to the end of a restricted period set by the compensation committee. A participant granted restricted stock generally has all of the rights of a shareholder, unless the compensation committee determines otherwise. During fiscal 2015, the Company awarded 234 shares of performance-based restricted stock to employees that vest three years from the date the performance targets are met. An additional 5 shares of performance-based restricted stock were granted to various employees that vest in one year if the performance targets are met. Additionally, an aggregate of 1 shares of non-performance based restricted stock were granted to several employees during fiscal 2015 that vest in one year. Awards that are subject to performance conditions are expensed based on the probability that these conditions will be achieved. The aggregate fair value of shares granted in fiscal 2015 was $2,183 . During fiscal 2014, the Company awarded 500 shares of performance-based restricted stock to employees that vest three years from the date the performance targets are met. An additional 84 shares of performance-based restricted stock were granted to various employees that vest in one year if the performance targets are met. Additionally, an aggregate of 27 shares of non-performance-based restricted stock were granted to several employees during fiscal 2014 that have vesting schedules that vary by grant and range from one through three years. The Company also granted 115 shares of non-performance-based restricted stock to directors, the terms of which allow for pro-rata vesting upon a director's retirement during the year in which the shares were issued. As all the directors are eligible for retirement, the Company recognized the compensation expense associated with these awards during 2015. Awards that are subject to performance conditions are expensed based on the probability that these conditions will be achieved. The aggregate fair value of 2014 granted shares was $5,674 . In fiscal 2015, the Company recorded compensation expense related to restricted stock grants of $1,532 . In fiscal 2014, compensation expense related to restricted stock grants was immaterial due to the awards only being outstanding for one day. The Company's policy is to recognize expense for awards subject to graded or cliff vesting using the straight-line attribution method. As of January 2, 2016 , the Company had unearned compensation cost related to unvested restricted stock awards of $6,207 which will be expensed through 2018. A summary of all restricted stock activity for the period indicated below is as follows: Number of Shares Weighted Average Grant Date Fair Value Unvested at January 3, 2015 726 $7.81 Vested — $— Granted 240 $9.09 Canceled (18) $7.81 Unvested at January 2, 2016 948 $8.13 No shares have vested since the Company's Spin-Off from SMI through January 2, 2016.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jan. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases. The Company has various operating leases, primarily for leased facilities. Total rental expense for these operating leases amounted to $500 , $551 and $571 in 2015, 2014 and 2013 , respectively. At January 2, 2016 , future minimum payments for operating leases with initial terms of one year or more are as follows: $527 in 2016; $494 in 2017; $154 in 2018; $15 in 2019; $5 in 2020 and nil thereafter. Unconditional Purchase Obligations. The Company has a contract to purchase finished instruments through August 2019. Based on contractual pricing at January 2, 2016 , the minimum purchase obligation totals $1,494 . Purchases under the contract totaled approximately $672 for fiscal 2015. These purchases are not in excess of our forecasted requirements. Legal & Environmental Matters. The Company is involved, from time to time, in various contractual, product liability, intellectual property and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Company, threatened, that the Company expects to have a material adverse effect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Company currently believes that the disposition of all pending or, to the knowledge of the Company, threatened claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity. Under the terms of the separation agreement between the Company and SMI, the Company agreed to indemnify SMI and its related entities from and against any and all liabilities relating to, arising out of or resulting from: any failure by the Company to pay, perform or otherwise promptly discharge any of the liabilities the Company agreed to assume with the Spin-Off; any of the Company's liabilities defined in the Merger Agreement; and any breach of any of the Merger Agreement, Separation Agreement or IP Cross-License Agreement. Liabilities that result from these obligations could result in significant, and in some cases uninsured, financial obligations. The Company does not believe this will have a significant impact on its financial position, results of operations or cash flows. In September 2013, Xodus Medical Inc., Alessio Pigazzi and Glenn Keilar (collectively “Xodus”) filed suit against Prime Medical, LLC (“Prime”), and Specialty Surgical Instrumentation, Inc. d/b/a Symmetry Surgical Inc. in the United States District Court for the Western District of Pennsylvania under cause number 2:13-cv-01372-AJS. In the lawsuit Xodus alleged that Prime, a manufacturer of products Symmetry Surgical distributes, had infringed on two of its patents, U.S. Patent No. 8,511,314 and US Patent No. 8,464,720 (the “Xodus Patents”) and that Symmetry Surgical was liable to it for damages resulting from selling products that infringed on the Xodus Patents. Symmetry Surgical’s Distribution Agreement with Prime provides Symmetry Surgical with full indemnification for these claims, and Prime has paid for all costs of litigation thus far. On February 24, 2014 the U.S. Patent and Trademarks Office ("USPTO") found substantial questions regarding the patentability of the Xodus Patents and on July 10, 2014 the USPTO rejected both of the Xodus Patents. Xodus has appealed to the full Board of the USPTO, a process that should be concluded in fiscal year 2016. Should the USPTO reverse its prior two findings, and should the US District Court find that Prime’s products infringe on the Xodus Patents, then Symmetry Surgical may be found liable to Xodus for some percentage of its sales of the Prime products, to the extent that Prime is unable to satisfy its indemnity obligations. On September 29, 2014, a purported class action complaint challenging the company’s former parent’s merger and the Company’s spin-out as a stand-alone public company was filed by Resolution Partners, an alleged stockholder of SMI, and all others similarly situated, in the Kosciusko Circuit Court in the state of Indiana. The complaint named as defendants Symmetry Medical Inc. (“SMI”), the members of the board of directors of SMI, Genstar Capital LLC, Tecomet’s sponsor (‘‘Genstar’’), Tecomet, Holdings and TecoSym Inc. The complaint generally alleges, among other things, that the members of the SMI board of directors breached their fiduciary duties to Resolution Partners and SMI stockholders during merger negotiations and by entering into the Merger Agreement and approving the Merger, and that Genstar and Tecomet allegedly aided and abetted such alleged breaches of fiduciary duties. The complaint further alleges that the joint proxy statement/prospectus filed by Symmetry Surgical with the SEC on September 5, 2014, which contained the preliminary proxy statement of SMI, was misleading or omitted certain allegedly material information. The complaint sought, among other relief, injunctive relief enjoining consummation of the Merger, compensatory and/or rescissory damages in an unspecified amount and costs and fees. The parties settled the suit prior to the consummation of the transaction, for no additional consideration and a few additional disclosures filed in a Form 8-k, although left the issue of a claim for fees and costs for resolution at a later time, either through agreement or via a court hearing. The Company has agreed with SMI to share equally in any fee award, up to 50% of the remaining insurance deductible. The Company does not believe this will have a significant impact on its financial position, results of operations or cash flows.

Net Income(Loss) Per Share

Net Income(Loss) Per Share	12 Months Ended
	Jan. 02, 2016
Earnings Per Share [Abstract]
Net Income(Loss) Per Share	Net Income(Loss) Per Share The following table sets forth the computation of earnings per share. Fiscal Year 2015 2014 2013 Net income (loss) for basic earnings per share: Income available to common shares -- Basic $ 1,200 $ (35,775 ) $ (12,185 ) Basic weighted average common shares outstanding 9,645 9,587 9,587 Net income (loss) attributable to common shareholders $ 0.12 $ (3.73 ) $ (1.27 ) Net income (loss) for diluted earnings per share: Income available to common shares -- Diluted $ 1,200 $ (35,775 ) $ (12,185 ) Basic weighted average common shares outstanding 9,645 9,587 9,587 Effect of dilution 43 — — Diluted weighted average common shares outstanding 9,688 9,587 9,587 Net income (loss) attributable to common shareholders $ 0.12 $ (3.73 ) $ (1.27 ) As of January 2, 2016, the diluted weighted average share calculation does not include performance based restricted stock awarded in fiscal 2014 and 2015 totaling 735 shares due to the performance criteria not being completed. For periods prior to the separation, the numerator for both basic and diluted earnings per share was net income (loss) attributable to the Company. The denominator for basic and diluted earnings per share was calculated using the number of shares of Symmetry Surgical common shares outstanding on the distribution date.

Product and Geographic Informat

Product and Geographic Information	12 Months Ended
	Jan. 02, 2016
Segment Reporting [Abstract]
Product and Geographic Information	Product and Geographic Information The Company has one operating segment which is the lowest level for which discrete financial information is available and the operating results are regularly reviewed by management. The Company sells a broad range of reusable stainless steel and titanium surgical hand-held instruments and retractor systems, sterile disposable surgical products (vein strippers, SECTO dissectors, tonsil sponges and surgical marker pens), and sterilization containers. These products are typically used in the surgical specialties of spine, general/OB-GYN, microsurgery/neurosurgery, orthopedics, laparoscopy, cardiovascular, thoracic and general surgery in the hospital setting as well as surgery centers and in select physician offices. These products are viewed in two categories by management; Symmetry Surgical Branded Products and Alliance Partners Products. Symmetry Surgical Branded Products include all products sold under brand names managed by the Company whereas Alliance Partners Products are brands the Company distributes for others in defined markets. Prior to the acquisition of the assets of Vesocclude Medical in August 2015, the revenue from the sales of Vesocclude product was depicted in the Alliance Partners product category. Upon acquisition, this revenue is now Symmetry Surgical branded product. For the purposes of comparability between periods, the historical product categories have been reclassified to include Vesocclude revenue in Symmetry Surgical branded product category. Revenues are attributed to geographic locations based on the location to which the Company ships its products. Revenues to External Customers: Fiscal Year 2015 2014 2013 United States $ 73,821 $ 71,578 $ 78,358 International 10,706 10,204 10,589 Total revenues $ 84,527 $ 81,782 $ 88,947 Revenues by Product: Fiscal Year 2015 2014 2013 Symmetry Surgical branded $ 76,935 $ 72,362 $ 74,671 Alliance Partners 7,592 9,420 14,276 Total revenues $ 84,527 $ 81,782 $ 88,947

Quarterly Results of Operations

Quarterly Results of Operations (Unaudited)	12 Months Ended
	Jan. 02, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results of Operations (Unaudited)	Quarterly Results of Operations (Unaudited) The Company’s fiscal year end is the 52 or 53 week period ending the Saturday closest to December 31. Fiscal year 2015 is a 52 week year ending January 2, 2016. Fiscal year 2014 was a 53 week year ending January 3, 2015. The Company’s interim quarters for fiscal 2015 and 2014 were 13 weeks long, except for the fourth quarter of fiscal 2014 which was 14 weeks. The following quarterly results of operations refer to these financial periods (in thousands, except per share data): Fiscal 2015 First Quarter Second Quarter Third Quarter Fourth Quarter (1) Fiscal Year (in thousands except per share data) Total revenue $ 20,774 $ 20,662 $ 20,951 $ 22,140 $ 84,527 Gross profit 9,885 9,809 9,956 9,800 39,450 Net income (loss) 756 341 255 (152 ) 1,200 Earnings per share: Basic $ 0.08 $ 0.04 $ 0.03 $ (0.02 ) $ 0.12 Diluted $ 0.08 $ 0.04 $ 0.03 $ (0.02 ) $ 0.12 Fiscal 2014 First Quarter Second Quarter (2) Third Quarter Fourth Quarter (2) Fiscal Year (in thousands except per share data) Total revenue $ 20,562 $ 20,473 $ 20,453 $ 20,294 $ 81,782 Gross profit 8,476 9,842 9,017 8,349 35,684 Net income (loss) (368 ) (6,146 ) 275 (29,536 ) (35,775 ) Earnings per share: Basic $ (0.04 ) $ (0.64 ) $ 0.03 $ (3.08 ) $ (3.73 ) Diluted $ (0.04 ) $ (0.64 ) $ 0.03 $ (3.08 ) $ (3.73 ) (1) The fourth quarter of 2015 net loss includes a pre-tax impairment charge of $1,014 . (2) The second and fourth quarters of 2014 net income (loss) include pre-tax asset impairment charges of $10,500 and $45,317 , respectively. The sum of the quarters may not equal the year to date amounts due to rounding. For periods prior to the separation, the weighted-average basic and diluted shares outstanding were based on the number of shares of Symmetry Surgical common stock outstanding on the distribution date.

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 02, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation. The consolidated and combined financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Year End	Year End . The Company’s fiscal year is the 52 or 53 week period ending on the Saturday closest to December 31. Fiscal year 2015 was a 52 week year (ending January 2, 2016 ), fiscal year 2014 was a 53 week year (ending January 3, 2015 ), and fiscal year 2013 was a 52 week year (ending December 28, 2013). References in these consolidated and combined financial statements to 2015, 2014 and 2013 refer to these financial periods, respectively.
Use of Estimates	Use of Estimates. Preparation of these consolidated and combined financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates, but management does not believe such differences will materially affect the Company's financial position or results of operations.
Business Combinations	Business Combinations. The Company records its business combinations under the acquisition method of accounting. Under the acquisition method of accounting, the Company allocates the purchase price of each acquisition to the tangible and identifiable intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition. The fair value of identifiable intangible assets is based upon detailed valuations that use various assumptions made by management. Any excess of the purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill.
Revenue Recognition	Revenue Recognition. The Company recognizes revenue on orders received from its customers when there is persuasive evidence of an arrangement with the customer that is supportive of revenue recognition, the customer has made a fixed commitment to purchase the product for a fixed or determinable price, collection is reasonably assured under the Company’s normal billing and credit terms and ownership and all risks of loss have been transferred to the buyer which is normally upon shipment or delivery to the customer. In certain circumstances, customer terms require receipt of product prior to the transfer of the risk of ownership. In such circumstances, revenue is not recognized upon shipment, but rather upon confirmation of delivery. For product sales to distributors, the Company recognizes revenue upon shipment to the distributor under standard contract terms stating that title to the goods passes to the distributors at point of shipment to the distributor’s location. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product. The Company offers certain customers volume rebates, which are reflected as a reduction in revenue when it is probable the rebate will be earned based on current and forecasted sales and the amount can be estimated. Product returns are estimated based upon historical return rates and are reflected as a reduction of revenue in the same period revenue is recognized.
Cash	Cash. Cash and cash equivalents include all highly liquid investments with a maturity of three months or less at the time of purchase.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts. The Company performs periodic credit evaluations of customers' financial condition and generally does not require collateral. Receivables are generally due within 30 to 90 days. The Company maintains an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. The Company makes estimates regarding the future ability of its customers to make required payments based on historical credit experience and expected future trends. Provisions to the allowance for doubtful accounts are charged to current selling and marketing expenses. Actual losses are charged against this allowance when incurred. The activity in the allowance for doubtful accounts was as follows: Fiscal Year Ended January 2, 2016 January 3, 2015 December 28, 2013 Balance as of beginning of period $ 306 $ 225 $ 483 Provision (recoveries) 37 481 (69 ) Write-offs (139 ) (400 ) (189 ) Balance as of end of period $ 204 $ 306 $ 225
Concentration of Credit Risk	Concentration of Credit Risk. On an on-going basis, the Company has no financial instruments that represent a concentration of credit risk.
Inventories	Inventories. Inventories are stated at the lower of cost, determined primarily on the first-in, first-out (FIFO) method, or market (net realizable value). Costs include material, labor and overhead costs, as applicable. Inventory balances are reviewed quarterly for excess products or obsolete inventory levels and written down, if necessary, to net realizable value.
Property and Equipment	Property and Equipment. Property and equipment are stated on the basis of cost. Depreciation is calculated on the straight-line method over the estimated useful lives of the respective assets. Accelerated methods are used for income tax purposes. Repair and maintenance costs are charged to expense as incurred. Upon retirement or sale of an asset, its cost and related accumulated depreciation are removed from the consolidated balance sheet and any gain or loss is recorded in operating income or expense.
Definite-Lived Long-Lived Assets	Definite-Lived Long-Lived Assets. The Company assesses the impairment of definite-lived long-lived assets when circumstances indicate the carrying value of an asset may not be recoverable based on the undiscounted future cash flows of an asset. If the carrying amount of the asset is determined not to be recoverable, a write-down to fair value is recorded. Fair values are determined based on quoted market values, undiscounted cash flows, or external appraisals, as applicable. The Company reviews long-lived assets for impairment at the individual asset or the asset group level for which the lowest level of independent cash flows can be identified. Intangible assets subject to amortization consist of trademarks and technology and patents which are amortized using the straight-line method, as well as customer related intangible assets which are amortized on an accelerated method. Straight-line methods are used for income tax purposes. All of the Company’s intangible assets were acquired in connection with its various acquisitions. The Company is required to reassess the expected useful lives of existing definite-lived assets annually. Impairment charges were recorded in fiscal 2015 related to two patents and one trademark of $252 and $762 , respectively. These assets were transitioned from Symmetry Medical during the Spin-Off and are no longer a key focus of the product portfolio given recent acquisitions and other areas of revenue growth. The Company reviewed all other definite-lived long-lived assets and did not record any impairment charges related to the remaining assets for fiscal 2015, 2014 or 2013 . The assessment of the recoverability of long-lived assets reflects management’s assumptions and estimates. Factors that management must estimate when performing impairment tests include sales volume, prices, inflation, discount rates, exchange rates, tax rates and capital spending. Significant management judgment is involved in estimating these factors, and they include inherent uncertainties. Measurement of the recoverability of these assets is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific reporting unit to which the assets are attributed. Changes in these estimates could change the conclusion regarding the impairment of other intangible assets or goodwill (as described below) and potentially result in a non-cash impairment in the future period. During fiscal 2013, all indefinite life intangible assets were evaluated and determined to be definite-lived assets and therefore assigned an appropriate useful life. In connection with the annual impairment test during fiscal 2013, the Company recognized an impairment charge related to certain trademarks and in-process research and development of $1,245 and $610 , respectively.
Goodwill	Goodwill. Goodwill recorded by the Company represents the purchase price in excess of the net assets of businesses acquired. Goodwill is not amortized but is tested for impairment annually on the first day of the fourth fiscal quarter and more frequently if circumstances warrant using a two-step process. The first step is a screen for potential impairment, while the second step measures the amount of impairment. Potential impairment is determined by comparing estimated fair value to the net book value of the reporting unit. Fair value is calculated using an income approach based on the present value of estimated future cash flows. The Company completed its impairment test and no impairment of goodwill existed in fiscal 2015. The Company recorded goodwill impairment charges in fiscal 2014 fiscal and 2013 totaling $55,817 and $18,250 , respectively.
Income Taxes	Income Taxes. Income taxes prior to the Spin-Off are presented on a separate return basis. Prior to the Spin-Off, the Company was included in the consolidated tax return of SMI. The consolidated and combined financial statements of the Company have been prepared using the assets and liability method in accounting for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities. Differences between the anticipated and actual outcomes of these future tax consequences could have a material impact on the consolidated results of operations or financial position of the Company. As a stand-alone entity, the Company files tax returns on its own behalf and its deferred taxes and effective tax rate may differ from those used in the historical periods. The Company did not maintain an income taxes payable to/from account with SMI. With the exception of certain entities outside the U.S. that transferred to the Company at separation, the Company is deemed to settle current tax balances with the SMI tax paying entities in the respective jurisdictions. These settlements are reflected as changes in net parent investment or net transfers to Symmetry Medical Inc. Additionally, tax planning strategies are utilized as part of the global tax compliance program of the Company. Judgments and interpretation of statutes are inherent in this process. The Company provides related reserves, where applicable, in accounting for uncertain tax positions. Interest and penalties associated with reserves for uncertain tax positions are classified in income tax expense in the statements of operations. During fiscal 2015, the Company identified an immaterial error in which deferred tax assets and additional paid-in capital were understated by $352 at the separation date from SMI in December 2014. The Company corrected the error in the accompanying January 3, 2015 consolidated balance sheet and consolidated and combined statements of equity.
Pensions	Pensions. The Company engages outside actuaries to assist in the determination of the obligation and cost under the plan which are direct obligations of the Company. The valuation of the funded status and the net period benefit cost for this plan is calculated using actuarial assumptions. The significant assumptions, which are reviewed annually, include the discount rate, compensation increases, turnover rates and health care cost trend rates. The significant assumptions used in determining these calculations are disclosed in Note 8 to the consolidated and combined financial statements. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method, in accordance with the rules for accounting for post-employment benefits.
Foreign Currency Transaction	Foreign Currency Translation. The financial statements of the Company's foreign subsidiaries are accounted for in local currency and have been translated into U.S. dollars in accordance with accounting guidance on foreign currency translation. Assets and liabilities have been translated using the exchange rate in effect at the balance sheet date. Revenues and expenses have been translated using a weighted-average exchange rate for the period. Currency translation adjustments have been recorded as a separate component of equity. Foreign currency transaction gains and losses resulting from a subsidiary's foreign currency denominated assets and liabilities included in other income were losses of $309 , $195 and $49 in fiscal 2015, 2014 and 2013 , respectively.
Shipping and Handling Costs	Shipping and Handling Costs. The Company reflects freight costs associated with shipping its products to customers as a component of cost of revenue.
Advertising Costs	Advertising Costs. Advertising costs are expensed as incurred and were $552 , $444 and $728 in fiscal 2015, 2014 and 2013 , respectively.
Research and Development Costs	Research and Development Costs. The Company recognizes costs associated with research and development (R&D) within general and administrative expenses in the consolidated and combined statements of operations. R&D costs were $1,174 , $721 and $864 in fiscal 2015, 2014 and 2013, respectively.
Derivative Financial Instruments	Derivative Financial Instruments. The Company recognizes all derivative instruments in its consolidated and combined financial statements at fair value. Changes in the fair value of derivatives are recorded each period in the derivative valuation loss line item of the consolidated and combined statements of operations unless the derivative qualifies for hedge accounting in which case the realized changes in fair value are reflected in the same financial statement line item of the item being hedged or the effective portion of changes in fair value of hedges is recorded each period in accumulated other comprehensive income (loss), net of tax, until the related hedge transaction occurs. Any ineffective portion of changes in fair value of the hedges is recorded in the derivative valuation loss line item of the statement of operations.
Stock-based Compensation	Stock-based compensation. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. Compensation cost for service-based awards is recognized ratably over the applicable service period. Compensation cost for performance-based awards is reassessed each period and recognized based upon the probability that the performance targets will be achieved. For restricted stock subject to service conditions or with performance targets, the fair market value of the award is determined based upon the closing value of the Company’s stock price on the grant date and the amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. For restricted stock with service conditions or with performance targets, the total expense recognized for each grant is only for those awards that ultimately vest.
Product Warranty	Product Warranty. The Company offers a limited warranty for its products with a coverage period that ranges between 1 year to lifetime for materials and workmanship. Warranty coverage varies depending on the product family. The Company’s policy is to accrue the estimated cost of warranty coverage at the time of the sale. The following table presents the change in the product warranty accrual included in other accrued expenses. Fiscal Year Ended January 2, 2016 January 3, 2015 December 28, 2013 Balance as of beginning of period $ 321 $ 555 $ 235 Provision for warranties issued in current year 157 201 105 Provision for (recover of) pre-existing warranty, net — (157 ) 325 Payments (129 ) (278 ) (110 ) Balance as of end of period $ 349 $ 321 $ 555
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies and the Company has chosen to take advantage of this extended transition period. Revenue from Contracts with Customers: In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 was originally effective for fiscal periods (including interim periods) beginning after December 15, 2016. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date by one year, with early adoption permitted as of the original effective date. ASU 2014-09 allows for either a full retrospective or a modified retrospective transition method. The Company is currently assessing the potential impact of the adoption of ASU 2014-09 on its financial statements and related disclosures. Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity : In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360), Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This update modifies the requirements for reporting discontinued operations. Under the amendments in ASU 2014-08, the definition of discontinued operation has been modified to only include those disposals of an entity that represent a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. This update also expands the disclosure requirements for disposals that meet the definition of a discontinued operation and requires entities to disclose information about disposals of individually significant components that do not meet the definition of discontinued operations. This update is effective for annual and interim periods beginning after December 15, 2014. The adoption of this ASU in fiscal 2015 by the Company did not have an impact on its financial position, results of operations or cash flows. Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. In June, 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This new guidance states that a performance target that affects vesting of a share-based payment and that could be achieved after the requisite service period is a performance condition under ASC 718. This update is effective for annual and interim periods beginning after December 15, 2015. The Company does not believe this ASU will have an impact on the Company's financial statements. Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In August, 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. This new guidance requires management to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The standard is effective for annual periods ending after December 15, 2016 with early adoption permitted. The Company does not believe this ASU will have an impact on the Company’s financial statements. Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This new guidance requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments of this standard are effective prospectively for the fiscal years, including interim periods, beginning after December 15, 2015, and early adoption is permitted. The Company adopted this ASU on January 3, 2016. Income Taxes (Topic 740) Related to the Balance Sheet Classification of Deferred Taxes. In November 2014 the FASB issued ASU 2015-17, Income Taxes (Topic 740) Related to the Balance Sheet Classification of Deferred Taxes which will require entities to present deferred tax assets (DTAs) and deferred tax liabilities (DTLs) as noncurrent in a classified balance sheet. The ASU simplifies the current guidance (ASC 740-10-45-4), which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet. The ASU is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods. The Board decided to allow all entities to early adopt the ASU for financial statements that had not been issued. Therefore, the Company adopted this ASU at January 2, 2016, and has reclassified all prior periods to be consistent with the requirements outlined in the ASU. The impact of the prior period reclassification was a $2,816 reduction of current assets, a $15 reduction of current liabilities and a net working capital decrease of $2,801 at January 3, 2015. Technical Corrections and Improvements . In June 2015, the FASB issued ASU No. 2015-10, Technical Corrections and Improvements to clarify that, for nonrecurring measurements estimated at a date during the reporting period other than the end of the reporting period, an entity should clearly indicate that the fair value information presented is not as of the period's end as well as the date or period that the measurement was taken. The Company adopted ASU 2015-10, effective June 12, 2015, as the change was effective upon issuance. The adoption did not have an impact on the Company's consolidated financial statements.

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jan. 02, 2016
Accounting Policies [Abstract]
Schedule Of Provision For Debt	The activity in the allowance for doubtful accounts was as follows: Fiscal Year Ended January 2, 2016 January 3, 2015 December 28, 2013 Balance as of beginning of period $ 306 $ 225 $ 483 Provision (recoveries) 37 481 (69 ) Write-offs (139 ) (400 ) (189 ) Balance as of end of period $ 204 $ 306 $ 225
Schedule of Product Warranty Liability	The following table presents the change in the product warranty accrual included in other accrued expenses. Fiscal Year Ended January 2, 2016 January 3, 2015 December 28, 2013 Balance as of beginning of period $ 321 $ 555 $ 235 Provision for warranties issued in current year 157 201 105 Provision for (recover of) pre-existing warranty, net — (157 ) 325 Payments (129 ) (278 ) (110 ) Balance as of end of period $ 349 $ 321 $ 555

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jan. 02, 2016
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets acquired and liabilities assumed based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Cash consideration $ 400 Contingent purchase liability No. 3, non-current 107 Fair value of total consideration $ 507 Inventory $ 102 Property and equipment 30 Acquired technology and patents 341 Non-compete 5 Net identifiable assets acquired $ 478 Goodwill $ 29 The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets acquired and liabilities assumed based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Net cash consideration $ 3,860 Contingent purchase liability No. 1, current 1,034 Contingent purchase liability No. 2, non-current 1,013 Pre-existing ownership interest 186 Gain on pre-existing ownership interest 67 Fair value of total consideration $ 6,160 Inventory $ 962 Property and equipment 252 Acquired customers 1,010 Trademarks 280 Acquired technology and patents 800 Other assets, non-current 637 Non-compete 25 Net identifiable assets acquired $ 3,966 Goodwill $ 2,194 Cash paid for acquisition $ 4,055 Cash received from seller related to previous ownership interest 195 Net cash transferred to seller upon closing $ 3,860

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jan. 02, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: January 2, January 3, Raw materials $ 1,032 $ 880 Work-in-process 141 530 Finished goods 21,903 22,731 $ 23,076 $ 24,141

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jan. 02, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, including depreciable lives, consists of the following: January 2, January 3, Buildings and improvements (20 to 40 years) $ 560 $ 575 Machinery and equipment (5 to 15 years) 1,816 1,499 Office equipment (3 to 5 years) 3,686 4,039 Construction-in-progress 10 43 6,072 6,156 Less accumulated depreciation (3,814 ) (3,388 ) $ 2,258 $ 2,768

Goodwill and Other Intangible35

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Jan. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Other than Goodwill	As of January 2, 2016 , the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets Acquired customers 19 years $ 92,355 $ (22,961 ) $ 69,394 Trademarks 13 years 4,014 (866 ) 3,148 Acquired technology, patents and other 13 years 1,521 (344 ) 1,177 Intangible assets subject to amortization 19 years $ 97,890 $ (24,171 ) $ 73,719 As of January 3, 2015 , the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets Acquired customers 19 years $ 91,438 $ (17,986 ) $ 73,452 Trademarks 10 years 4,815 (730 ) 4,085 Acquired technology and patents 13 years 1,220 (854 ) 366 Intangible assets subject to amortization 19 years $ 97,473 $ (19,570 ) $ 77,903
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Intangible asset amortization expense for fiscal 2015, 2014 and 2013 was $5,562 , $5,375 and $5,027 , respectively, and is included in general and administrative expenses in the consolidated and combined statements of operations. At January 2, 2016, the annual amortization expense for intangible assets recorded as of January 2, 2016 is anticipated to be as follows for each of the next 5 fiscal years: 2016 $ 5,400 2017 5,427 2018 5,378 2019 5,321 2020 5,262
Schedule of Goodwill	The reconciliation of the beginning and ending carrying amounts of goodwill are as follows: Balance as of December 28, 2013 $ 62,995 Impairment of goodwill (55,817 ) Effects of foreign currency (52 ) Balance as of January 3, 2015 $ 7,126 Acquisitions 2,223 Effects of foreign currency (8 ) Balance as of January 2, 2016 $ 9,341

Employee Benefit Plan (Tables)

Employee Benefit Plan (Tables)	12 Months Ended
	Jan. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Pension Cost	The components of net periodic pension cost for fiscal 2015 are as follows: Fiscal Year Ended 2015 2014 2013 Components of Net Periodic Pension Cost: Service cost $ 40 $ 46 $ 50 Interest cost 20 26 22 Amortization of net actuarial loss 19 9 16 Net periodic pension cost $ 79 $ 81 $ 88 Weighted average assumptions used to determine net periodic pension cost: Discount rate 2.40 % 3.60 % 3.00 % Salary increases 2.50 % 2.50 % 2.50 %
Schedule of Changes in Projected Benefit Obligations	The change in the projected benefit obligation and the funded status of the plan and a reconciliation of such funded status to the amounts reported in the consolidated balance sheets as of January 2, 2016 and January 3, 2015 is as follows: Fiscal Year Ended 2015 2014 2013 Change in projected benefit obligation Benefit obligation, beginning of year $ 900 $ 813 $ 793 Service cost 40 46 50 Interest cost 20 26 22 Actuarial (gain) loss (85 ) 106 (117 ) Foreign currency exchange rate changes (71 ) (91 ) 65 Benefit obligation, end of year $ 804 $ 900 $ 813 Change in fair value of assets: Fair value of plan assets, beginning of year $ — $ — $ — Fair value of plan assets, end of year — — — Funded status at end of year - under funded $ (804 ) $ (900 ) $ (813 )
Defined Benefit Plans and Other Postretirement Benefit Plans	Fiscal Year Ended 2015 2014 2013 Change in projected benefit obligation Benefit obligation, beginning of year $ 900 $ 813 $ 793 Service cost 40 46 50 Interest cost 20 26 22 Actuarial (gain) loss (85 ) 106 (117 ) Foreign currency exchange rate changes (71 ) (91 ) 65 Benefit obligation, end of year $ 804 $ 900 $ 813 Change in fair value of assets: Fair value of plan assets, beginning of year $ — $ — $ — Fair value of plan assets, end of year — — — Funded status at end of year - under funded $ (804 ) $ (900 ) $ (813 ) The following summarizes the Company's balance sheet related pension and other benefit plan accounts at January 2, 2016 as compared to accounts at January 3, 2015 : Fiscal Year Ended 2015 2014 Non-current benefit liability $ 804 $ 900 Accumulated other comprehensive loss, net of tax $ 154 $ 238
Schedule of Amounts Recognized in Accumulated Other Comprehensive Income	The amounts recognized in accumulated other comprehensive income as of January 2, 2016 and January 3, 2015 was as follows: Fiscal Year Ended 2015 2014 2013 Net actuarial (gain) loss $ (85 ) $ 106 $ (117 ) Less: Tax expense (benefit) 1 (65 ) 53 Accumulated other comprehensive (income) loss impact $ (84 ) $ 41 $ (64 ) Weighted average assumptions used to determine benefit obligation: Discount rate 2.49 % 2.40 % 3.60 % Salary increases 2.80 % 2.50 % 2.50 %

Fair Value of Financial Instr37

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Jan. 02, 2016
Fair Value Disclosures [Abstract]
Schedule of Liabilities Measured on Recurring Basis	The fair value and carrying value of the Company's liabilities measured at fair value on a recurring basis is as follows (None at January 3, 2015): January 2, 2016 Fair Value Measurements Level 1 Level 2 Level 3 Total Liabilities Contingent purchase liability No. 1 $ — $ — $ 1,047 $ 1,047 Contingent purchase liability No. 2 1,029 1,029 Contingent purchase liability No. 3 — — 107 107 Total liabilities $ — $ — $ 2,183 $ 2,183

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Jan. 02, 2016
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income is comprised of gains (losses) resulting from currency translations of foreign entities and pension plan actuarial gains and losses, net of tax. Other comprehensive income consists of the following: Foreign Currency Translation Pension Plan Actuarial Loss, net of tax Other Comprehensive Income (loss) Balance at December 28, 2013 $ 36 $ (197 ) $ (161 ) Other comprehensive income (loss) (305 ) (41 ) (346 ) Balance at January 3, 2015 (269 ) (238 ) (507 ) Other comprehensive income (loss) (109 ) 84 (25 ) Balance at January 2, 2016 $ (378 ) $ (154 ) $ (532 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jan. 02, 2016
Income Tax Disclosure [Abstract]
Schedule of Income before Income Taxes	Income before income taxes consisted of: Fiscal Year Ended 2015 2014 2013 Domestic $ 795 $ (57,545 ) $ (19,016 ) Foreign 684 1,114 390 $ 1,479 $ (56,431 ) $ (18,626 )
Schedule of Deferred Tax Liabilities	Significant components of the Company’s net deferred tax assets are as follows: January 2, 2016 January 3, 2015 Deferred tax asset Compensation $ 708 $ 162 Inventory 2,320 2,317 Loss carryforwards 3,555 2,555 Intangibles 17,442 19,139 Other 514 624 Total deferred tax asset 24,539 24,797 Deferred tax liability Property and equipment (254 ) (401 ) Total deferred tax liabilities (254 ) (401 ) Deferred tax assets, net $ 24,285 $ 24,396
Schedule of Components of Income Tax Provision	Significant components of the income tax provision are as follows: Fiscal Year 2015 2014 2013 Current: Federal $ — $ — $ (1,435 ) State 31 40 159 Foreign 176 148 50 207 188 (1,226 ) Deferred 72 (20,844 ) (5,215 ) $ 279 $ (20,656 ) $ (6,441 )
Schedule of Income Tax Reconciliation	The provision for income taxes differs from that computed at the federal statutory rate of 34% in 2015 and 35% in 2014 and 2013 as follows: Fiscal Year 2015 2014 2013 Tax at Federal statutory rate $ 503 $ (19,747 ) $ (6,519 ) State income taxes 81 (1,618 ) (552 ) Change in state deferred tax rate (231 ) — — Foreign income taxes (95 ) (250 ) 103 Goodwill impairment — 871 310 Other 21 88 217 $ 279 $ (20,656 ) $ (6,441 )

Stock-Based Compensation Plans

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Jan. 02, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Restricted Stock Activity	A summary of all restricted stock activity for the period indicated below is as follows: Number of Shares Weighted Average Grant Date Fair Value Unvested at January 3, 2015 726 $7.81 Vested — $— Granted 240 $9.09 Canceled (18) $7.81 Unvested at January 2, 2016 948 $8.13

Net Income(Loss) Per Share (Tab

Net Income(Loss) Per Share (Tables)	12 Months Ended
	Jan. 02, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of earnings per share. Fiscal Year 2015 2014 2013 Net income (loss) for basic earnings per share: Income available to common shares -- Basic $ 1,200 $ (35,775 ) $ (12,185 ) Basic weighted average common shares outstanding 9,645 9,587 9,587 Net income (loss) attributable to common shareholders $ 0.12 $ (3.73 ) $ (1.27 ) Net income (loss) for diluted earnings per share: Income available to common shares -- Diluted $ 1,200 $ (35,775 ) $ (12,185 ) Basic weighted average common shares outstanding 9,645 9,587 9,587 Effect of dilution 43 — — Diluted weighted average common shares outstanding 9,688 9,587 9,587 Net income (loss) attributable to common shareholders $ 0.12 $ (3.73 ) $ (1.27 )

Product and Geographic Inform42

Product and Geographic Information (Tables)	12 Months Ended
	Jan. 02, 2016
Segment Reporting [Abstract]
Schedule of Revenue from External Customers	Revenues to External Customers: Fiscal Year 2015 2014 2013 United States $ 73,821 $ 71,578 $ 78,358 International 10,706 10,204 10,589 Total revenues $ 84,527 $ 81,782 $ 88,947
Schedule of Product Revenue	Revenues by Product: Fiscal Year 2015 2014 2013 Symmetry Surgical branded $ 76,935 $ 72,362 $ 74,671 Alliance Partners 7,592 9,420 14,276 Total revenues $ 84,527 $ 81,782 $ 88,947

Quarterly Results of Operatio43

Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Jan. 02, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following quarterly results of operations refer to these financial periods (in thousands, except per share data): Fiscal 2015 First Quarter Second Quarter Third Quarter Fourth Quarter (1) Fiscal Year (in thousands except per share data) Total revenue $ 20,774 $ 20,662 $ 20,951 $ 22,140 $ 84,527 Gross profit 9,885 9,809 9,956 9,800 39,450 Net income (loss) 756 341 255 (152 ) 1,200 Earnings per share: Basic $ 0.08 $ 0.04 $ 0.03 $ (0.02 ) $ 0.12 Diluted $ 0.08 $ 0.04 $ 0.03 $ (0.02 ) $ 0.12 Fiscal 2014 First Quarter Second Quarter (2) Third Quarter Fourth Quarter (2) Fiscal Year (in thousands except per share data) Total revenue $ 20,562 $ 20,473 $ 20,453 $ 20,294 $ 81,782 Gross profit 8,476 9,842 9,017 8,349 35,684 Net income (loss) (368 ) (6,146 ) 275 (29,536 ) (35,775 ) Earnings per share: Basic $ (0.04 ) $ (0.64 ) $ 0.03 $ (3.08 ) $ (3.73 ) Diluted $ (0.04 ) $ (0.64 ) $ 0.03 $ (3.08 ) $ (3.73 ) (1) The fourth quarter of 2015 net loss includes a pre-tax impairment charge of $1,014 . (2) The second and fourth quarters of 2014 net income (loss) include pre-tax asset impairment charges of $10,500 and $45,317 , respectively.

Description of the Business (De

Description of the Business (Details) - USD ($) $ in Thousands	Dec. 01, 2015	Aug. 28, 2015	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Business Acquisition [Line Items]
Cash consideration			$ 4,260	$ 0	$ 0
Vesocclude Medical, LLC (Vesocclude) [Member]
Business Acquisition [Line Items]
Cash consideration		$ 4,055
Minority interest		4.80%
Potential payments based on achievements		$ 2,047
Insightra® Medical [Member]
Business Acquisition [Line Items]
Cash consideration	$ 400
Royalty on future sales, fair value	$ 107
Maximum [Member] | Vesocclude Medical, LLC (Vesocclude) [Member]
Business Acquisition [Line Items]
Potential payments based on achievements		$ 2,200

Summary of Significant Accoun45

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Summary of Accounting Policies [Line Items]
Number of weeks in fiscal year	365 days	371 days	365 days
Goodwill, impairment		$ 55,817	$ 18,250
Intangible assets, impairment	$ 1,014	55,817	20,105
Deferred tax assets, net	24,285	24,396
Foreign currency transaction gain (loss)	309	195	49
Advertising expense	552	444	728
Research and development costs	1,174	721	864
Deferred finance costs, net	346	434
Restatement Adjustment [Member]
Summary of Accounting Policies [Line Items]
Deferred tax assets, net		352
Additional paid in capital		352
New Accounting Pronouncement, Early Adoption, Effect [Member] | Other Current Assets [Member]
Summary of Accounting Policies [Line Items]
Deferred finance costs, net		2,816
New Accounting Pronouncement, Early Adoption, Effect [Member] | Other Current Liabilities [Member]
Summary of Accounting Policies [Line Items]
Deferred finance costs, net		15
New Accounting Pronouncement, Early Adoption, Effect [Member] | Working Capital [Member]
Summary of Accounting Policies [Line Items]
Deferred finance costs, net		$ 2,801
Patents
Summary of Accounting Policies [Line Items]
Intangible assets, impairment	252
Trademarks [Member]
Summary of Accounting Policies [Line Items]
Intangible assets, impairment	$ 762		1,245
In Process Research and Development [Member]
Summary of Accounting Policies [Line Items]
Intangible assets, impairment			$ 610

Summary of Significant Accoun46

Summary of Significant Accounting Policies (Allowance for Doubtful Accounts Receivable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance as of beginning of period	$ 306	$ 225	$ 483
Provision (recoveries)	37	481	(69)
Write-offs	(139)	(400)	(189)
Balance as of end of period	$ 204	$ 306	$ 225

Summary of Significant Accoun47

Summary of Significant Accounting Policies (Product Warranty) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance as of beginning of period	$ 321	$ 555	$ 235
Provision for warranties issued in current year	157	201	105
Provision for (recover of) pre-existing warranty, net	0	(157)	325
Payments	(129)	(278)	(110)
Balance as of end of period	$ 349	$ 321	$ 555

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Thousands	Dec. 01, 2015	Aug. 28, 2015	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Business Acquisition [Line Items]
Cash consideration			$ 4,260	$ 0	$ 0
Discount rate			12.00%	15.00%	12.50%
Other Income [Member]
Business Acquisition [Line Items]
Difference between fair values and equity method carrying value of investment		$ 0
Vesocclude Medical, LLC (Vesocclude) [Member]
Business Acquisition [Line Items]
Cash consideration		$ 4,055
Minority interest		4.80%
Potential payments based on achievements		$ 2,047
Percent of assets and liabilities acquired at their fair values		100.00%
Discount rate		18.61%
Pre-tax fair value charge			$ 26
Vesocclude Medical, LLC (Vesocclude) [Member] | Medical Device [Member]
Business Acquisition [Line Items]
Minority interest		20.00%
Vesocclude Medical, LLC (Vesocclude) [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential payments based on achievements		$ 2,200
Potential undiscounted amount of each future payment		2,200
Vesocclude Medical, LLC (Vesocclude) [Member] | Minimum [Member]
Business Acquisition [Line Items]
Potential undiscounted amount of each future payment		$ 0
Insightra® Medical [Member]
Business Acquisition [Line Items]
Cash consideration	$ 400
Royalty on future sales, fair value	$ 107

Acquisitions (Schedule of Asset

Acquisitions (Schedule of Assets and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Dec. 01, 2015	Aug. 28, 2015	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Business Acquisition [Line Items]
Goodwill			$ 9,341	$ 7,126	$ 62,995
Cash paid for acquisition			$ 4,260	$ 0	$ 0
Vesocclude Medical, LLC (Vesocclude) [Member]
Business Acquisition [Line Items]
Cash paid for acquisition		$ 4,055
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member]
Business Acquisition [Line Items]
Contingent purchase liability No. 1, current		1,034
Contingent purchase liability No. 2, non-current		1,013
Pre-existing ownership interest		186
Gain on pre-existing ownership interest		67
Fair value of total consideration		6,160
Inventory		962
Property and equipment		252
Other assets, non-current		637
Net identifiable assets acquired		3,966
Goodwill		2,194
Cash paid for acquisition		4,055
Cash received from seller related to previous ownership interest		195
Net cash transferred to seller upon closing		3,860
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Acquired Customers [Member]
Business Acquisition [Line Items]
Net identifiable assets acquired		1,010
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Trademarks [Member]
Business Acquisition [Line Items]
Net identifiable assets acquired		280
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Acquired Technology and Patents [Member]
Business Acquisition [Line Items]
Net identifiable assets acquired		800
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Net identifiable assets acquired		$ 25
Insightra® Medical [Member]
Business Acquisition [Line Items]
Cash paid for acquisition	$ 400
Insightra® Medical [Member] | Level 3 [Member]
Business Acquisition [Line Items]
Contingent purchase liability No. 3, non-current	107
Fair value of total consideration	507
Inventory	102
Property and equipment	30
Net identifiable assets acquired	478
Goodwill	29
Cash paid for acquisition	400
Insightra® Medical [Member] | Level 3 [Member] | Acquired Technology and Patents [Member]
Business Acquisition [Line Items]
Net identifiable assets acquired	341
Insightra® Medical [Member] | Level 3 [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Net identifiable assets acquired	$ 5

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jan. 02, 2016	Jan. 03, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 1,032	$ 880
Work-in-process	141	530
Finished goods	21,903	22,731
Inventory, net	$ 23,076	$ 24,141

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 6,072	$ 6,156
Less accumulated depreciation	(3,814)	(3,388)
Property and equipment, net	2,258	2,768
Buildings and Improvement [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 560	575
Buildings and Improvement [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	20 years
Buildings and Improvement [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,816	1,499
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	15 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,686	4,039
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Construction-in-Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10	$ 43

Goodwill and Other Intangible52

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, impairment	$ 1,014,000	$ 55,817,000	$ 20,105,000
Goodwill, impairment		$ 55,817,000	18,250,000
Impairment of intangible assets (including goodwill)			$ 20,105,000
Discount rate	12.00%	15.00%	12.50%
Amortization of intangible assets	$ 5,562,000	$ 5,375,000	$ 5,027,000
Accumulated impairment losses	$ 74,067,000	74,067,000
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, impairment		$ 0	$ 1,855,000
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Revenue growth rate		3.00%	3.00%
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Revenue growth rate		5.00%	6.00%
For the Year 2016 and beyond [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Revenue growth rate	0.00%
For the Year 2016 and beyond [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Revenue growth rate	5.70%

Goodwill and Other Intangible53

Goodwill and Other Intangible Assets (Intangibe Assets, other than Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	19 years	19 years
Gross Intangible Assets	$ 97,890	$ 97,473
Accumulated Amortization	(24,171)	(19,570)
Net Intangible Assets	73,719	77,903
Total	$ 73,719	$ 77,903
Acquired Customers [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	19 years	19 years
Gross Intangible Assets	$ 92,355	$ 91,438
Accumulated Amortization	(22,961)	(17,986)
Net Intangible Assets	$ 69,394	$ 73,452
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	13 years	10 years
Gross Intangible Assets	$ 4,014	$ 4,815
Accumulated Amortization	(866)	(730)
Net Intangible Assets	$ 3,148	$ 4,085
Acquired Technology and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	13 years	13 years
Gross Intangible Assets	$ 1,521	$ 1,220
Accumulated Amortization	(344)	(854)
Net Intangible Assets	$ 1,177	$ 366

Goodwill and Other Intangible54

Goodwill and Other Intangible Assets (Intangible Assets, Amortization Expense) (Details) $ in Thousands	Jan. 02, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 5,400
2,017	5,427
2,018	5,378
2,019	5,321
2,020	$ 5,262

Goodwill and Other Intangible55

Goodwill and Other Intangible Assets (Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Goodwill [Roll Forward]
Balance	$ 7,126	$ 62,995
Impairment of goodwill		(55,817)	$ (18,250)
Acquisitions	2,223
Effects of foreign currency	(8)	(52)
Balance	$ 9,341	$ 7,126	$ 62,995

Employee Benefit Plan (Componen

Employee Benefit Plan (Components of Net Periodic Pension Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Components of Net Periodic Pension Cost:
Service cost	$ 40	$ 46	$ 50
Interest cost	$ 20	$ 26	$ 22
Weighted average assumptions used to determine net periodic pension cost:
Discount rate	2.49%	2.40%	3.60%
Salary increases	2.80%	2.50%	2.50%
Pension Cost [Member]
Components of Net Periodic Pension Cost:
Service cost	$ 40	$ 46	$ 50
Interest cost	20	26	22
Amortization of net actuarial loss	19	9	16
Net periodic pension cost	$ 79	$ 81	$ 88
Weighted average assumptions used to determine net periodic pension cost:
Discount rate	2.40%	3.60%	3.00%
Salary increases	2.50%	2.50%	2.50%

Employee Benefit Plan (Change i

Employee Benefit Plan (Change in Projected Benefit Obligation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Change in projected benefit obligation
Benefit obligation, beginning of year	$ 900	$ 813	$ 793
Service cost	40	46	50
Interest cost	20	26	22
Actuarial (gain) loss	(85)	106	(117)
Foreign currency exchange rate changes	(71)	(91)	65
Benefit obligation, end of year	804	900	813
Change in fair value of assets:
Fair value of plan assets, beginning of year	0	0	0
Fair value of plan assets, end of year	0	0	0
Funded status at end of year - under funded	$ (804)	$ (900)	$ (813)

Employee Benefit Plan (Balance

Employee Benefit Plan (Balance Sheet Related Pension and Other Benefit Plan Accounts ) (Details) - USD ($) $ in Thousands	Jan. 02, 2016	Jan. 03, 2015
Compensation and Retirement Disclosure [Abstract]
Non-current benefit liability	$ 804	$ 900
Accumulated other comprehensive loss, net of tax	$ 154	$ 238

Employee Benefit Plan (Amounts

Employee Benefit Plan (Amounts Recognized in Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Compensation and Retirement Disclosure [Abstract]
Net actuarial (gain) loss	$ (85)	$ 106	$ (117)
Less: Tax expense (benefit)	1	(65)	53
Accumulated other comprehensive income impact	$ (84)	$ 41	$ (64)
Weighted average assumptions used to determine benefit obligation:
Discount rate	2.49%	2.40%	3.60%
Salary increases	2.80%	2.50%	2.50%

Employee Benefit Plan (Narrativ

Employee Benefit Plan (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015
Compensation and Retirement Disclosure [Abstract]
Accumulated benefit obligation	$ 660	$ 732
Net actuarial loss for the pension plan required to be amortized from accumulated other comprehensive income into net periodic pension cost	$ 13

Fair Value of Financial Instr61

Fair Value of Financial Instruments (Details) - Recurring Basis [Member] $ in Thousands	Oct. 03, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase liability No. 1	$ 1,047
Contingent purchase liability No. 2	1,029
Contingent purchase liability No. 3	107
Total liabilities	2,183
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase liability No. 1	0
Contingent purchase liability No. 3	0
Total liabilities	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase liability No. 1	0
Contingent purchase liability No. 3	0
Total liabilities	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase liability No. 1	1,047
Contingent purchase liability No. 2	1,029
Contingent purchase liability No. 3	107
Total liabilities	$ 2,183

Debt Arrangements (Narrative) (

Debt Arrangements (Narrative) (Details)	12 Months Ended
	Jan. 02, 2016USD ($)	Jan. 03, 2015USD ($)
Debt Instrument [Line Items]
Deferred debt issuance costs	$ 346,000	$ 434,000
Revolving Credit Facility [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	20,000,000
Amount outstanding	$ 0	$ 3,876,000
Fixed charge coverage ratio	1.25
Liquidity Requirement under Agreements	$ 1,500,000
Unused borrowing capacity	$ 13,735,000,000
Revolving Credit Facility [Member] | Secured Debt [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3.25%
Revolving Credit Facility [Member] | Secured Debt [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%

Accumulated Other Comprehensi63

Accumulated Other Comprehensive Income (Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Changes in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	$ (507)	$ (161)
Other comprehensive income (loss)	(25)	(346)	$ 97
Ending balance	(532)	(507)	(161)
Foreign Currency Translation [Member]
Changes in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(269)	36
Other comprehensive income (loss)	(109)	(305)
Ending balance	(378)	(269)	36
Pension Plan Actuarial Loss, Net of Tax [Member]
Changes in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(238)	(197)
Other comprehensive income (loss)	84	(41)
Ending balance	$ (154)	$ (238)	$ (197)

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Related Party Transaction [Line Items]
Sales	$ 0	$ 678	$ 71
Symmetry Medical Inc. [Member]
Related Party Transaction [Line Items]
Sales	678	71
Purchases	6,714	5,381
Expenses	$ 5,996	$ 6,832

Income Taxes (Income Before Inc

Income Taxes (Income Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Income Tax Disclosure [Abstract]
Domestic	$ 795	$ (57,545)	$ (19,016)
Foreign	684	1,114	390
Income (loss) before income taxes	$ 1,479	$ (56,431)	$ (18,626)

Income Taxes (Net Deferred Tax

Income Taxes (Net Deferred Tax Liabilities) (Details) - USD ($) $ in Thousands	Jan. 02, 2016	Jan. 03, 2015
Deferred tax asset
Compensation	$ 708	$ 162
Inventory	2,320	2,317
Loss carryforwards	3,555	2,555
Intangibles	17,442	19,139
Other	514	624
Total deferred tax asset	24,539	24,797
Deferred tax liability
Property and equipment	(254)	(401)
Total deferred tax liabilities	(254)	(401)
Deferred tax assets, net	$ 24,285	$ 24,396

Income Taxes (Components of Inc

Income Taxes (Components of Income Tax Provision) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Income Tax Disclosure [Abstract]
Federal	$ 0	$ 0	$ (1,435)
State	31	40	159
Foreign	176	148	50
Current	207	188	(1,226)
Deferred	72	(20,844)	(5,215)
Total	$ 279	$ (20,656)	$ (6,441)

Income Taxes (Provision for Inc

Income Taxes (Provision for Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Income Tax Disclosure [Abstract]
Tax at Federal statutory rate	$ 503	$ (19,747)	$ (6,519)
State income taxes	81	(1,618)	(552)
Change in state deferred tax rate	(231)	0	0
Foreign income taxes	(95)	(250)	103
Goodwill impairment	0	871	310
Other	21	88	217
Total	$ 279	$ (20,656)	$ (6,441)

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Income Tax Disclosure [Line Items]
Federal statutory income tax rate	35.00%	34.00%	35.00%
Deferred tax assets	$ 24,539	$ 24,797
Undistributed earnings of foreign subsidiaries	1,702
Income before income taxes	1,479	$ (56,431)	$ (18,626)
To be Achieved Prior to Expiration of Net Operating Loss Carryforwards [Member]
Income Tax Disclosure [Line Items]
Income before income taxes	63,000
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforwards	8,432
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforwards	18,160
Deferred tax assets	$ 3,555

Profit Sharing Plan (Details)

Profit Sharing Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Profit Sharing Plan [Abstract]
Maximum annual contribution per employee, percent	50.00%
Maximum annual contribution per employee, amount	$ 4
Administrative and employer match expenses	$ 222	$ 260	$ 265

Stock-Based Compensation Plan71

Stock-Based Compensation Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,532,000	$ 717,000	$ 625,000
Equity Incentive Plan (the Plan) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock are reserved for issuance	1,250
Fair value of shares granted	2,183,000	5,674,000
Equity Incentive Plan (the Plan) [Member] | Performance Based Restricted Stock [Member] | Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares awarded	234	500
Vesting period	3 years	3 years
Shares granted	5	84
Equity Incentive Plan (the Plan) [Member] | Performance Based Restricted Stock [Member] | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year	1 year
Equity Incentive Plan (the Plan) [Member] | Non-Performance Based Restricted Stock [Member] | Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares awarded	1	27
Vesting period	1 year
Equity Incentive Plan (the Plan) [Member] | Non-Performance Based Restricted Stock [Member] | Employee [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Equity Incentive Plan (the Plan) [Member] | Non-Performance Based Restricted Stock [Member] | Employee [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Equity Incentive Plan (the Plan) [Member] | Non-Performance Based Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted		115
Equity Incentive Plan (the Plan) [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,532
Unallocated share based compensation	$ 6,207,000

Stock-Based Compensation Plan72

Stock-Based Compensation Plans (Restricted Stock Activity) (Details) - Restricted Stock [Member]	12 Months Ended
	Jan. 02, 2016$ / sharesshares
Number of Shares
Unvested at January 3, 2015 | shares	726
Vested | shares	0
Granted | shares	240
Canceled | shares	(18)
Unvested at January 2, 2016 | shares	948
Weighted Average Grant Date Fair Value
Unvested at January 3, 2015 | $ / shares	$ 7.81
Vested | $ / shares	0
Granted | $ / shares	9.09
Canceled | $ / shares	7.81
Unvested at January 2, 2016 | $ / shares	$ 8.13

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 500	$ 551	$ 571
Operating leases, future minimum payments receivable, 2015	527
Operating leases, future minimum payments receivable, 2016	494
Operating leases, future minimum payments receivable, 2017	154
Operating leases, future minimum payments receivable, 2018	15
Operating leases, future minimum payments receivable, 2019	5
Operating leases, future minimum payments receivable, thereafter	0
Unconditional purchase obligations contract price	1,494
Unrecorded unconditional purchase obligation, purchases	$ 672

Net Income(Loss) Per Share (Com

Net Income(Loss) Per Share (Computation of Earnings per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended								12 Months Ended			24 Months Ended
		Jan. 02, 2016	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Jan. 03, 2015	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013	Jan. 02, 2016
Net income (loss) for basic earnings per share:
Income available to common shares -- Basic										$ 1,200	$ (35,775)	$ (12,185)
Basic weighted average common shares outstanding (in shares)	[1]									9,645	9,587	9,587
Net income (loss) attributable to common shareholders		$ (0.02)	$ 0.03	$ 0.04	$ 0.08	$ (3.08)	$ 0.03	$ (0.64)	$ (0.04)	$ 0.12	$ (3.73)	$ (1.27)
Net income (loss) for diluted earnings per share:
Income available to common shares -- Diluted										$ 1,200	$ (35,775)	$ (12,185)
Basic weighted average common shares outstanding (in shares)	[1]									9,645	9,587	9,587
Effect of dilution										43	0	0
Diluted weighted average common shares outstanding (in shares)	[1]									9,688	9,587	9,587
Net income (loss) attributable to common shareholders		$ (0.02)	$ 0.03	$ 0.04	$ 0.08	$ (3.08)	$ 0.03	$ (0.64)	$ (0.04)	$ 0.12	$ (3.73)	$ (1.27)
Performance-based shares excluded in the calculation of diluted EPS													735
[1]	On December 5, 2014, SMI distributed 9,587 shares of Symmetry Surgical common stock. For periods prior to the separation, the weighted-average basic and diluted shares outstanding were based on the number of shares of Symmetry Surgical common stock outstanding on the distribution date. Refer to Note 19 for information regarding the calculation of basic and diluted net income per share for the year ended January 3, 2015.

Product and Geographic Inform75

Product and Geographic Information (Narrative) (Details)	12 Months Ended
	Jan. 02, 2016segment
Segment Reporting [Abstract]
Number of reportable segments	2

Product and Geographic Inform76

Product and Geographic Information (Revenues to External Customers) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jan. 02, 2016	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Jan. 03, 2015	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 22,140	$ 20,951	$ 20,662	$ 20,774	$ 20,294	$ 20,453	$ 20,473	$ 20,562	$ 84,527	$ 81,782	$ 88,947
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									73,821	71,578	78,358
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									$ 10,706	$ 10,204	$ 10,589

Product and Geographic Inform77

Product and Geographic Information (Sale by Product) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jan. 02, 2016	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Jan. 03, 2015	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Segment Reporting Information [Line Items]
Total revenues	$ 22,140	$ 20,951	$ 20,662	$ 20,774	$ 20,294	$ 20,453	$ 20,473	$ 20,562	$ 84,527	$ 81,782	$ 88,947
Symmetry Surgical Branded [Member]
Segment Reporting Information [Line Items]
Total revenues									76,935	72,362	74,671
Alliance Partners [Member]
Segment Reporting Information [Line Items]
Total revenues									$ 7,592	$ 9,420	$ 14,276

Quarterly Results of Operatio78

Quarterly Results of Operations (Unaudited) (Narrative) (Details)	3 Months Ended								12 Months Ended
	Jan. 02, 2016	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Jan. 03, 2015	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Quarterly Financial Information Disclosure [Abstract]
Number of weeks in fiscal year									365 days	371 days	365 days
Number of weeks in interim quarter	98 days	91 days	91 days	91 days	91 days	91 days	91 days	98 days

Quarterly Results of Operatio79

Quarterly Results of Operations (Unaudited) (Quarterly Results of Operations) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jan. 02, 2016	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Jan. 03, 2015	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Jan. 02, 2016	Jan. 03, 2015	Dec. 28, 2013
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$ 22,140	$ 20,951	$ 20,662	$ 20,774	$ 20,294	$ 20,453	$ 20,473	$ 20,562	$ 84,527	$ 81,782	$ 88,947
Gross profit	9,800	9,956	9,809	9,885	8,349	9,017	9,842	8,476	39,450	35,684	40,553
Net income (loss)	$ (152)	$ 255	$ 341	$ 756	$ (29,536)	$ 275	$ (6,146)	$ (368)	$ 1,200	$ (35,775)	$ (12,185)
Earnings per share:
Basic (in dollars per share)	$ (0.02)	$ 0.03	$ 0.04	$ 0.08	$ (3.08)	$ 0.03	$ (0.64)	$ (0.04)	$ 0.12	$ (3.73)	$ (1.27)
Diluted (in dollars per share)	$ (0.02)	$ 0.03	$ 0.04	$ 0.08	$ (3.08)	$ 0.03	$ (0.64)	$ (0.04)	$ 0.12	$ (3.73)	$ (1.27)
Asset impairment charges	$ 1,014				$ 45,317		$ 10,500